Sant Pau - Institut de Recerca

Main lines of research

Biologic therapy in dermatology.
Genome-wide association studies in psoriasis.
Medical and physical treatment options for vascular tumours.
Psychopathological studies of patients with chronic dermatological disorders.
Innate and acquired immunologically-mediated dermatological.

Challenges

Ensure a stable clinical research infrastructure and staff.
Foster interdepartmental collaborative research.

Group coordination

PUIG SANZ, LUIS FGS
lpuig@santpau.cat

Members

Altemir Vidal, Arcadi FGS
Bravo Gonzalez, Marina IR
Diaz-Salazar Monreal, Maria IR
Flores Climente, Victor Adrian IR
Fuentes Garcia, Ruben IR
Garces Gatnau, Joan Ramon FGS
Garcia Muret, Maria Pilar FGS
Gely Vila, Cristina IR
Iznardo Ruiz, Helena FGS
Lopez Ferrer, Anna FGS
Lopez Sanchez, Cristina FGS
Morales Munera, Caridad Elena FGS
Roe Crespo , Esther FGS
Ruiz Salas, Veronica FGS
Rusiñol Batlle, Lluis FGS
Serra Baldrich, Esther FGS
Spertino , Jorge Luis FGS
Vilarrasa Rull, Eva FGS
Yelamos Pena, Oriol FGS

Publications 2023

(JIF 2022)

-Armario JC, Carrascosa JM, Flórez Á, Herranz P, Pereyra JJ, Serra E, Silvestre JF, Comellas M, Isidoro O, Ortiz de Frutos FJ. Pruritus and Pain Constitute the Main Negative Impact of Atopic Dermatitis From the Patient’s Perspective: A Systematic Review. Dermatitis. 2023; DOI:10.1089/derm.2023.0163. PMID:37751176. IF:5,200 (Q1/2D). Document type: Review.

-Artime E, Serra E, Mert C, Díaz S, Huete T, Hernández I, Lledo L, Sicras A. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain. Actas Dermo-Sifiliograficas. 2023; 114(1):T9-T18. DOI:10.1016/j.ad.2022.08.025. PMID:36368579. Document type: Article.

-Berenguer S, Aparicio M, Herranz P, Ruíz R, López A, Santos J, Rodríguez Fernández L, Hospital M, Arias S, Carretero G, Mateu A, Ferran M, del Alcázar E, Santos S, Garcia FJ, Belinchón I, González Á, Ruíz D, Eiris N, Rocamora V, Rivera R, de la Cueva P, Daudén E, Salgado L, Llamas M. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19468. PMID:37625815. IF:9,200 (Q1/1D). Document type: Article.

-Berna E, ABBAD C, Garcia Á, Palacios D, Ballester A, Carrascosa J-M, DE LA CUEVA P, Anton C, Azcarraga C, Garcia E, DE NICOLAS B, Puig L, Jaen P, Mehta NN, Gelfand JM, Gonzalez Á. Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians. ACTA DERMATO-VENEREOLOGICA. 2023; 103:adv5087. DOI:10.2340/actadv.v103.5087. PMID:36987537. IF:3,600 (Q1/3D). Document type: Article.

-Blanco G, López D, Pujol RM, Gómez A, Puiggros A, López M, Estrach T, García MP, López I, Servitje O, Bellosillo B, Muro M, Espinet B, Rabionet R, Gallardo F. High-throughput RNA sequencing of the T cell receptor alpha and beta chains for simultaneous clonality and biological analyses in Sezary syndrome. JOURNAL OF CLINICAL LABORATORY ANALYSIS. 2023; 37(23-24)DOI:10.1002/jcla.24982. PMID:38115685. IF:2,700 (Q2/5D). Document type: Article.

-Blauvelt A, Thyssen JP, Guttman E, Bieber T, Serra E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan M, Garcia E, Silverberg JI. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(6)DOI:10.1093/bjd/ljad022. PMID:36994947. IF:10,300 (Q1/1D). Document type: Article.

-Camina G, Mateu L, López A, Puig L. Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives. Patient Preference and Adherence. 2023; 17DOI:10.2147/PPA.S350760. PMID:37408843. IF:2,200 (Q3/7D). Document type: Review.

-Carmona E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Epidermolysis bullosa acquisita induced by atezolizumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; DOI:10.1111/ddg.15203. PMID:37658659. IF:3,600 (Q1/3D). Document type: Letter.

-Carmona E, Puig L. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. Immunotherapy. 2023; 15(15)DOI:10.2217/imt-2023-0013. PMID:37609785. IF:2,800 (Q4/8D). Document type: Article.

-Carmona E, Puig L. The biological basis of disease recurrence in psoriasis. Italian Journal of Dermatology and Venereology. 2023; 158(4)DOI:10.23736/S2784-8671.23.07583-7. PMID:37404193. IF:1,900 (Q3/7D). Document type: Review.

-Carmona E, Sullivan I, Yélamos O. Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response. MELANOMA RESEARCH. 2023; 33(6)DOI:10.1097/CMR.0000000000000918. PMID:37890183. IF:2,200 (Q3/7D). Document type: Letter.

-Carrascosa JM, Vilarrasa E, Belinchon I, Herranz P, Crespo J, Guimera F, Olveira A, Trabajoparael GRP. Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts. Actas Dermo-Sifiliograficas. 2023; 114(5)DOI:10.1016/j.ad.2023.01.004. PMID:36720362. Document type: Article.

-Castellanos M, Bris BB, Marsol IB, Campos MM, Ruiz R, Llorente CP, Nuno A, Sanchez JT, Mur EC, Garcia RG, Alonso AB, Espanol GA, Garcia YH, Schmidt JMS, Sanchez MA, Crespo ER, Alonso ED, Gallo G, Izquierdo J, Varillas D. Pradiktive Faktoren fur Anti-MDA5-Antikorper bei Patienten mit Dermatomyositis: eine retrospektive multizentrische Studie. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; 21(7):21. DOI:10.1111/ddg.15089_g. PMID:37427730. IF:3,600 (Q1/3D). Document type: Article.

-Castillo E, Ríos R, Aràjol C, Gely C, Márquez L, Calafat M, González C, Cañete F, Mesonero F, Guardiola J, Garcia E, Mañosa M, Domènech E. Clinical and endoscopic outcomes of patients with colonic Crohn’s disease treated with 5-aminosalicylates as monotherapy. Gastroenterologia y Hepatologia. 2023; 46(3)DOI:10.1016/j.gastrohep.2022.09.003. PMID:36179946. IF:1,900 (Q4/10D). Document type: Article.

-Choon SE, Elewski BE, Fujita H, Geng S, van de Kerkhof P, Mburu S, Puig L, Romiti R, Venturini M. Diversity in the clinical presentation of generalized pustular psoriasis (GPP): A series of case vignettes from around the world. EXPERIMENTAL DERMATOLOGY. 2023; 32(8)DOI:10.1111/exd.14794. PMID:36999936. IF:3,600 (Q1/3D). Document type: Article.

-Costanzo A, Llamas M, Fabbrocini G, Cuccia A, Rivera R, Du KG, Kasujee I, Puig L, Carrascosa JM. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(10)DOI:10.1111/jdv.19229. PMID:37246505. IF:9,200 (Q1/1D). Document type: Article.

-Docampo A, Sanchez MJ, Pastor MA, Gimenez A, Rodriguez M, Serra E, Miquel J, Sanchez J, Sanz T, Zaragoza V, Sanchez P, Carrascosa JM, Gatica ME, Fernandez V, Cordoba S, Gonzalez R, Silvestre JF. Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain. Dermatitis. 2023; 34(4)DOI:10.1089/derm.2022.0023. PMID:37001174. IF:5,200 (Q1/2D). Document type: Article.

-Egeberg A, Kristensen LE, Puig L, Rich P, Smith SD, Garrelts A, See K, Holzkaemper T, Fotiou K, Schuster C. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks. JOURNAL OF DERMATOLOGICAL TREATMENT. 2023; 34(1):2263108. DOI:10.1080/09546634.2023.2263108. PMID:37781881. IF:2,900 (Q2/4D). Document type: Article.

-Egeberg A, Merola JF, Schäkel K, Puig L, Mahar PD, Wang IY, Pavo I, Schuster C, Griffiths CEM. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 2023; 9:1092688. DOI:10.3389/fmed.2022.1092688. PMID:36777159. IF:3,900 (Q2/4D). Document type: Article.

-Escale A, Yelamos O, Vidal J, Fuster A, Catalina QM, Borve A, Aguilar R, Fusta X, Cubiro X, Rafat ME, Lopez C, Marin FX. Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care. Scientific Reports. 2023; 13(1):4293. DOI:10.1038/s41598-023-31340-1. PMID:36922556. IF:4,600 (Q2/4D). Document type: Article.

-Eyerich K, Krueger J, Stahle M, Schakel K, Conrad C, Armstrong A, Gniadecki R, Puig L, Scoble T, Williams N. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19652. PMID:38071690. IF:9,200 (Q1/1D). Document type: Letter.

-Falkenhain D, Muniesa C, Estrach MT, Morillo M, Penate Y, Acebo E, Pujol RM, Garcia MP, Machan S, Medina S, Botella R, de Misa RF, Blanes M, Florez A, Perez G, Izu R, Yanguas I, Silva E, Perez A, Prieto L, Zayas A, Parera ME, Perez A, Aspe L, Roman C, Sanchez MP, Bassas J, Dominguez JD, Calzado L, Navedo M, Ortiz A, Servitje O, Polo I, Torres I, Hernandez MN, Mitxelena J, Garcia A, Garcia I, Ortiz PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermo-Sifiliograficas. 2023; 114(4)DOI:10.1016/j.ad.2022.11.013. PMID:36848951. Document type: Article.

-Fustà X, García A, Yélamos O. [Translated article] BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis [Tumor melanocítico inactivado a BAP1: claves para su diagnóstico dermatoscópico]. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2022.11.008. PMID:36464005. Document type: Article.

-Geat D, Gisondi P, Maurelli M, Puig L, Paul C, Thaci D, Iversen L, Bellinato F, Girolomoni G. Price variability of TNF-a inhibitor biosimilars among European countries. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19756. PMID:38108512. IF:9,200 (Q1/1D). Document type: Letter.

-Gely C, Gordillo J, Bertoletti F, González C, López A, García E. Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients. Gastroenterologia y Hepatologia. 2023; 46(5)DOI:10.1016/j.gastrohep.2022.10.005. PMID:36243252. IF:1,900 (Q4/10D). Document type: Article.

-Girolomoni G, Savage L, Gisondi P, Svensson Å, Mahé E, Augustin M, Puig L. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and Therapy. 2023; 13(10)DOI:10.1007/s13555-023-01014-x. PMID:37710078. IF:3,400 (Q2/3D). Document type: Review.

-Gisondi P, Puig L, Richard MA, Paul C, Nijsten T, Taieb C, Stratigos A, Trakatelli M, Salavastru C, EADV Burden of Skin Diseases Project T. Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the ‘burden of skin diseases’ EADV project. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37 Suppl 7DOI:10.1111/jdv.18917. PMID:37806002. IF:9,200 (Q1/1D). Document type: Article.

-Gisondi P, Simon D, Alarcon I, Pournara E, Puig L. Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. JOURNAL OF DERMATOLOGICAL TREATMENT. 2023; 34(1):2167487. DOI:10.1080/09546634.2023.2167487. PMID:36625506. IF:2,900 (Q2/4D). Document type: Review.

-Gonzalez A, Boehncke WH, De Sutter J, Zamorano JL, Lambert J, Puig L. Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(9)DOI:10.1111/jdv.19191. PMID:37259959. IF:9,200 (Q1/1D). Document type: Article.

-Gonzalez M, Puertolas T, Martinez C, Carrera C, Seral CM, Rodriguez P, Sequero S, Cerezuela P, Ochoa RF, Munoz E, Basa MA, Martin J, Soria A, Moreno JFR, Marquez I, Criado PL, Manzano JL, Lopez R, De Miguel PA, Villalobos L, Algarra SM, Gonzalez I, Boada A, Castano AG, Puig S, Crespo G, Fra PL, Zamora CA, Rodriguez MF, Valles L, Drozdowskyj A, Gardeazabal J, Fernandez LA, Rodrigo A, Cruz R, Yelamos O, Rubio B, Mujica K, Provencio M, Berrocal A, Spanish Melanoma GEM GRP. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02985-7. PMID:36566266. IF:3,400 (Q3/6D). Document type: Article.

-Hernández CP, Borrego L, Mercader P, Giménez AM, Sánchez J, Silvestre JF, González R, Sanz T, Sánchez A, Melé G, Zaragoza V, Miquel FJ, Carrascosa JM, Córdoba S, Gatica ME, Ruiz I, Serra E, Tous F, Rodríguez M, Pastor MA, Pérez P, Hervella M, de Vega M, García I. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation. CONTACT DERMATITIS. 2023; 88(3)DOI:10.1111/cod.14251. PMID:36403138. IF:5,500 (Q1/1D). Document type: Article.

-Iznardo H, Bernal S, Boronat S, Roé E. Sclerotic Bone Lesions as a Clue in the Diagnosis of Three Generations of Tuberous Sclerosis Complex: Case Report and Review of Literature. PEDIATRIC NEUROLOGY. 2023; 148DOI:10.1016/j.pediatrneurol.2023.07.022. PMID:37634327. IF:3,800 (Q1/2D). Document type: Article.

-Iznardo H, Roe E, Serra E, Puig L. Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics. 2023; 15(2):385. DOI:10.3390/pharmaceutics15020385. PMID:36839707. IF:5,400 (Q1/2D). Document type: Review.

-Kirkham BW, Egeberg A, Behrens F, Pinter A, Merola JF, Holzkaemper T, Gallo G, Ng KJ, Bolce R, Schuster C, Nash P, Puig L. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Rheumatology and Therapy. 2023; 10(5)DOI:10.1007/s40744-023-00553-1. PMID:37400681. IF:3,800 (Q3/6D). Document type: Review.

-Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Korber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Gomez NN, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(3)DOI:10.1093/bjd/ljac089. PMID:36751950. IF:10,300 (Q1/1D). Document type: Article.

-Koren J, Lambert JLW, Thomsen SF, McAteer H, Fabbrocini G, Corazza V, Jullien D, Augustin M, Warren RB, de Rie MA, Lazaridou E, Puig L, Guillevin L, Grosser M, Boehncke WH. Elevating the Standard of Care for Patients with Psoriasis: ‘Calls to Action’ from Epicensus, a Multistakeholder Pan-European Initiative. Dermatology and Therapy. 2023; 13(1)DOI:10.1007/s13555-022-00846-3. PMID:36484915. IF:3,400 (Q2/3D). Document type: Article.

-Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra E, Lapeere H, Ahmad F, Lopez ZKJ, Piketty C, Ständer S, OLYMPIA 2. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(17)DOI:10.1056/NEJMoa2301333. PMID:37888917. IF:158,500 (Q1/1D). Document type: Article.

-Langenbruch A, Mohr N, Andrees V, Kessens I, Reich A, Czarnecka M, Puig L, Dauden E, Iversen L, Augustin M. PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries. ACTA DERMATO-VENEREOLOGICA. 2023; 103:adv6532. DOI:10.2340/actadv.v103.6532. PMID:37649411. IF:3,600 (Q1/3D). Document type: Article.

-Longo C, Lippolis N, Lai M, Spadafora M, Kaleci S, Condorelli AG, Lombardi M, Pampena R, Argenziano G, Nazzaro G, Scalvenzi M, Akay BN, Broganelli P, Fargnoli MC, Paoli J, Yélamos O, Pellacani G, Borsari S, Lallas A. Dermoscopic features of trichoepithelioma: A multicentre observational case-control study conducted by the International Dermoscopy Society. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(10):e1253-e1255. DOI:10.1111/jdv.19262. PMID:37326166. IF:9,200 (Q1/1D). Document type: Letter.

-Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, Daniele F, Brnabic A, Reed C, Wilhelm S, Holzkamper T, Schuster C, Puig L. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting. ADVANCES IN THERAPY. 2023; 40(3)DOI:10.1007/s12325-022-02379-9. PMID:36515803. IF:3,800 (Q2/4D). Document type: Article.

-Maravilla P, Merino M, Alfonso S, Balea J, Carrascosa JM, Delgado O, Dolz F, García A, Herranz P, Manfredi A, Martínez J, Morales de los Ríos Luna P, Puig L, Ros S, Hidalgo Á. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health. 2023; 11:1000776. DOI:10.3389/fpubh.2023.1000776. PMID:36778548. IF:5,200 (Q1/2D). Document type: Article.

-Marti I, Podlipnik S, Cañueto J, Ferrándiz C, Deza G, Sanmartín O, Jaka A, Beà S, Botella R, Redondo P, Turrión L, Ruiz V, Masferrer E, Yébenes M, Sánchez J-M, Gracia I, Altemir A, Aguayo RS, Becerril S, Bodet D, Leal L, Fuente MJ, Moreno OM, Abril C, Tomás A, Sandoval A, Toll A. Prognostic factors for satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: A multicentric cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(1)DOI:10.1016/j.jaad.2023.02.048. PMID:36907554. IF:13,800 (Q1/1D). Document type: Article.

-Martos L, Llamas M, Armesto S, Herrera E, Vidal D, Vilarrasa E, Rivera R, de la Cueva P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Baniandres O, Feltes R, Alsina M, Dauden E. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(3):e146-e149. DOI:10.1111/ijd.16365. PMID:35867958. IF:3,600 (Q1/3D). Document type: Letter.

-Mateu L, Puig L. Genetic and Epigenetic Mechanisms of Psoriasis. Genes. 2023; 14(8):1619. DOI:10.3390/genes14081619. PMID:37628670. IF:3,500 (Q2/4D). Document type: Review.

-Mateu L, Rusinol L, Puig L. Reddish and edematous nodules in an immunosuppressed patient. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(7)DOI:10.1111/ijd.16512. PMID:36371702. IF:3,600 (Q1/3D). Document type: Note.

-Montero T, Garces JR, Rodriguez MA, Ruiz V, de Eusebio E, Minano R, Escutia B, Gonzalez B, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, de la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Vilarrasa E, Sanchez P, Lopez JL, Botella R, Feal JC, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, Sanmartin O, REGESMOHS E. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(8)DOI:10.1111/jdv.19056. PMID:36950898. IF:9,200 (Q1/1D). Document type: Article.

-Moreno OM, Bea S, Mayo F, Perez G, Torres I, Bonfill M, Deza G, Ruiz V, Masferrer E, Feal C, Turrion L, Toll A, Yebenes M, Galiano S, Jaka A, Ferrandiz C, Florez A, Hernandez N, Fernandez R, Rios L, Sanmartin O. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study. Actas Dermo-Sifiliograficas. 2023; 114(7):T565-T571. DOI:10.1016/j.ad.2023.06.011. PMID:37302483. Document type: Article.

-Muniesa C, Gallardo F, García I, Estrach MT, Combalia A, Morillo M, De la Cruz F, Machan S, Moya C, Rovira R, Sanchez B, Acebo E, Amutio E, Penate Y, Losada MD, García MP, Iznardo H, Román C, Canueto J, Fernández R, Flórez Á, Izu RM, Torres I, Zayas A, Pérez G, Blanes M, Yanguas JI, Pérez A, Callejas M, Ortiz PL, Pérez A, Prieto L, González E, Servitje O. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(1)DOI:10.1111/jdv.18563. PMID:36017748. IF:9,200 (Q1/1D). Document type: Article.

-Navarro A, Gracia T, Almagro M, De la Fuente S, Florez Á, Yélamos O, Montero T, González C, Diago A, Abadías I, Fuentelsaz V, Colmenero M, Banuls J, Arias S, Buendía A, Almenara M, Gil P, Gilaberte Y. A multicenter case-control study comparing sun exposure habits and use of photoprotection measures in patients diagnosed with different types of skin cancer. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE. 2023; 39(5)DOI:10.1111/phpp.12878. PMID:37130164. IF:2,600 (Q2/5D). Document type: Article.

-Navarro A, Gracia T, Almagro M, de la Fuente S, Flórez A, Yélamos O, Montero T, González C, Diago A, Abadías I, Fuentelsaz V, Colmenero M, Bañuls J, Arias S, Buendía A, Almenara M, Gil P, Gilaberte Y. The Influence of the Exposome in the Cutaneous Squamous Cell Carcinoma, a Multicenter Case-Control Study. Cancers. 2023; 15(22):5376. DOI:10.3390/cancers15225376. PMID:38001636. IF:5,200 (Q2/3D). Document type: Article.

-Navarro V, Puig L, Vidal S, Ramírez J, Llamas M, Fernández C, Almodóvar R, Pinto JA, Galíndez E, Zarco P, Joven B, Gratacós J, Juanola X, Blanco R, Arias S, Sanz J, Queiro R, Canete JD. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Frontiers in Immunology. 2023; 14:1191782. DOI:10.3389/fimmu.2023.1191782. PMID:37600764. IF:7,300 (Q1/3D). Document type: Review.

-Olveira A, Augustin S, Benlloch S, Ampuero J, Suárez JA, Armesto S, Vilarrasa E, Belinchón I, Herranz P, Crespo J, Guimerá F, Gómez L, Martín V, Carrascosa JM. The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. Life-Basel. 2023; 13(2):419. DOI:10.3390/life13020419. PMID:36836776. IF:3,200 (Q2/4D). Document type: Review.

-Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(6)DOI:10.1016/j.jaad.2023.07.1024. PMID:37553030. IF:13,800 (Q1/1D). Document type: Article.

-Pereira MP, Weisshaar E, Halvorsen JA, Wallengren J, Legat FJ, Garcovich S, Savk E, Reich A, Bozek A, Lvov A, Bobko S, Metz M, Streit M, Misery L, Brenaut E, Serra E, Gonçalo M, Szepietowski JC, Augustin M, Nau T, Zeidler C, Ständer S. Chronic prurigo: Insufficient disease control in spite of high healthcare usage. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(6):e808-e812. DOI:10.1111/jdv.18903. PMID:36682045. IF:9,200 (Q1/1D). Document type: Letter.

-Pereyra JJ, Baldrich ES, Ruiz R, Torres EB, Dobao PD, Nart IF, Menéndez AF, Martin A, Miquel JM, Silvestre JF, Armario JC. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus. ACTA DERMATO-VENEREOLOGICA. 2023; 103:adv12314. DOI:10.2340/actadv.v103.12314. PMID:37982727. IF:3,600 (Q1/3D). Document type: Article.

-Pereyra JJ, Herranz P, Figueras I, Perez B, Elosua M, Munera M, Melgosa J, Zaragoza V, Silvestre JF, Campos M, Guilabert A, Miquel J, Alcantara S, de la Cueva P, Serra E, Armario JC. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2023; 33(3)DOI:10.18176/jiaci.0831. PMID:35671128. IF:7,200 (Q1/2D). Document type: Note.

-Pereyra J-J, Herranz P, Ruiz R, Elosua M, Galán M, Figueras I, Miquel J, de la Cueva P, Serra E, Munera M, Melé G, Expósito V, Perez B, Serrano A, Ortiz de Frutos JF, Armario JC. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(9)DOI:10.1093/ced/llad153. PMID:37098171. IF:4,100 (Q1/2D). Document type: Article.

-Pereyra JJ, Poveda JL, Rivero A, Serra E, Silvestre JF, Armario JC, Calleja MÁ, Carrascosa JM, Flórez Á, Herranz P, Comellas M, Ortiz de Frutos FJ. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19432. PMID:37594914. IF:9,200 (Q1/1D). Document type: Letter.

-Puig L, Choon SE, Gottlieb AB, Marrakchi S, Prinz JC, Romiti R, Tada Y, von D, Gooderham M. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(4)DOI:10.1111/jdv.18851. PMID:36606566. IF:9,200 (Q1/1D). Document type: Article.

-Puig L, Costanzo A, de Jong E, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2023; DOI:10.1007/s40257-023-00816-1. PMID:37804472. IF:7,300 (Q1/1D). Document type: Article.

-Puig L, Daudén E, Cuervas M, Novella C, Guisado C. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19403. PMID:37567861. IF:9,200 (Q1/1D). Document type: Article.

-Puig L. Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(2):ljac081. DOI:10.1093/bjd/ljac081. PMID:36763894. IF:10,300 (Q1/1D). Document type: Editorial Material.

-Puig L. Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology. Actas Dermo-Sifiliograficas. 2023; 114(10)DOI:10.1016/j.ad.2023.07.013. PMID:37482290. Document type: Letter.

-Quirke S, Weinman J, Cook ES, Yiu ZZN, Dand N, Langan SM, Bechman K, Tsakok T, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Barbosa IA, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di P, Gisondi P, Jullien D, Lambert J, Naldi L, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Galloway JB, Griffiths C, Barker JN, Norton S, Smith CH, Mahil SK, PsoProtect GRP. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(5)DOI:10.1093/bjd/ljac144. PMID:36763806. IF:10,300 (Q1/1D). Document type: Article.

-Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Stratigos A, Trakatelli M, Puig L, EADV Burden of Skin Diseases Project T. The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37 Suppl 7DOI:10.1111/jdv.18916. PMID:37806003. IF:9,200 (Q1/1D). Document type: Article.

-Richard MA, Wolkenstein P, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Trakatelli M, Puig L, Stratigos A, EADV burden of skin diseases project T. Ethnicity and skin conditions in Europe: a large survey from the “Burden of Skin Diseases” EADV project. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(11)DOI:10.1111/jdv.18994. PMID:36840384. IF:9,200 (Q1/1D). Document type: Letter.

-Rivera R, Dauden E, Carrascosa JM, de la Cueva P, Puig L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatology and Therapy. 2023; 13(3)DOI:10.1007/s13555-022-00881-0. PMID:36635445. IF:3,400 (Q2/3D). Document type: Review.

-Rivera R, Pozo T, Alfageme F, Díaz B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad C, Romaní J, Martorell A, Fernández P, Romero C, Molina A. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermo-Sifiliograficas. 2023; 114(9):T755-T762. DOI:10.1016/j.ad.2023.06.018. PMID:37479135. Document type: Article.

-Ruiz R, Galán M, Llamas M, Salgado L, Puig L, de la Cueva P, Carrascosa JM, en representación (GPS). Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis. Actas Dermo-Sifiliograficas. 2023; 114(6)DOI:10.1016/j.ad.2023.02.016. PMID:36906260. Document type: Article.

-Ruiz V, Podlipnik S, Sandoval A, Sanmartin O, Bernia E, Bonfill M, Bassas P, Yebenes M, Florez A, Sola J, Just M, Aguayo RS, Niubo E, Quintana M, Deza G, Jaka A, Fuentes MJ, Canueto J, Toll A. Real-world experience with vismodegib on advanced and multiple BCCs: data from the RELIVIS study. DERMATOLOGY. 2023; 239(5)DOI:10.1159/000530813. PMID:37257423. IF:3,400 (Q2/3D). Document type: Article.

-Rusinol L, Carmona E, Puig L. Durability and long-term outcomes of biologic therapies in psoriasis. Expert Review of Clinical Immunology. 2023; 20(1):2250918. DOI:10.1080/1744666X.2023.2250918. PMID:37610817. IF:4,400 (Q2/5D). Document type: Review.

-Rusinol L, Carmona E, Puig L. Psoriasis: a focus on upcoming oral formulations. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2023; 32(7)DOI:10.1080/13543784.2023.2242767. PMID:37507233. IF:6,100 (Q1/2D). Document type: Review.

-Rusinol L, Carmona E, Spertino J. Bullous eruption in a pluripathological patient. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(5):e312-e313. DOI:10.1111/ijd.16590. PMID:36683133. IF:3,600 (Q1/3D). Document type: Letter.

-Rusiñol L, Mozos A, Yélamos O. Disseminated Monomorphic Pink Papules. JAMA Dermatology. 2023; 159(12)DOI:10.1001/jamadermatol.2023.3586. PMID:37938840. IF:10,900 (Q1/1D). Document type: Editorial Material.

-Rusinol L, Puig L. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(4):3391. DOI:10.3390/ijms24043391. PMID:36834806. IF:5,600 (Q1/3D). Document type: Review.

-Ryan C, Puig L, Zema C, Thompson EHZ, Yang M, Wu E, Bensimon A, Huang X, Joshi AD, Elewski B. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(1)DOI:10.1016/j.jaad.2021.12.032. PMID:34954285. IF:13,800 (Q1/1D). Document type: Article.

-Sahuquillo A, Hospital M, Vilarrasa E, Llamas M, Rivera R, Carrascosa JM, de la Cueva P, Armesto S, Ruíz R, Velasco M, Magdaleno J, Yanguas JI, Ribera M, Salgado L, Herranz P, Romero A, Martínez E, López JL, Ballescá F, Botella R. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 2023; DOI:10.1111/ajd.14130. PMID:37435962. IF:2,000 (Q3/7D). Document type: Article.

-Sanchez G, Puig L. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(12):10305. DOI:10.3390/ijms241210305. PMID:37373452. IF:5,600 (Q1/3D). Document type: Review.

-Sans L, Figueras I, García I, Bonfill M, Guilabert A, Curto L, Bertolín M, Ferran M, Serra E, Pujol RM, Santamaria LF. Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients. Frontiers in Immunology. 2023; 14:1124018. DOI:10.3389/fimmu.2023.1124018. PMID:36993985. IF:7,300 (Q1/3D). Document type: Article.

-Sanz T, Giménez AM, Mercader P, Perez RG, Zaragoza V, Miquel J, Silvestre JF, Córdoba S, Carrascosa JM, Gática ME, Ruíz I, Tous F, Ortiz FJ, Serra E, Pastor A, Rodríguez M, Sánchez J, Gilo AS, Melé G, Guillén PSP, García I, Borrego L. Sodium metabisulfite a current low relevant allergen in Spain. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19702. PMID:38088580. IF:9,200 (Q1/1D). Document type: Letter.

-Schneller L, Vergara E, Martorell A, Romaní J, Lázaro M, Vilarrasa E, Díaz B, Vázquez I, Segura JM, Azaña JM, González MA, Cañueto J, Molina A, Leiva M, Navarro FJ, Sánchez J, Pascual JC. Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(5):e271-e272. DOI:10.1016/j.jaad.2019.03.006. PMID:30872153. IF:13,800 (Q1/1D). Document type: Letter.

-Segura S, Podlipnik S, Boada A, Martí RM, Sabat M, Yélamos O, Zarzoso I, Azón A, López D, Solà J, Baliu C, Galvany L, Pasquali P, Just M, Duran X, Carrera C, Richarz NA, Pujol RM, Malvehy J, Puig S, Network of Melanoma Centres of C. Melanoma-specific survival in worse in the elderly: a multicentric cohort study. MELANOMA RESEARCH. 2023; 33(6)DOI:10.1097/CMR.0000000000000923. PMID:37696262. IF:2,200 (Q3/7D). Document type: Article.

-Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, Katoh N, Peris K, Puig L, Barbarot S, Mark T, Steffensen LA, Tindberg A-M, Wollenberg A. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2023; 24(6)DOI:10.1007/s40257-023-00806-3. PMID:37682422. IF:7,300 (Q1/1D). Document type: Article.

-Strober B, Paul C, Blauvelt A, Thaçi D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Gomez NN, Eyerich K. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(3)DOI:10.1016/j.jaad.2023.04.063. PMID:37182701. IF:13,800 (Q1/1D). Document type: Article.

-Taleb E, Yélamos O, Ardigo M, Christensen RE, Geller S. Non-invasive Skin Imaging in Cutaneous Lymphomas. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2023; DOI:10.1007/s40257-023-00824-1. PMID:37964050. IF:7,300 (Q1/1D). Document type: Review.

-Tous F, Gimenez AM, Sanz T, Perez RG, Carrascosa JM, Zaragoza V, Cordoba S, Gatica ME, Miquel J, Borrego L, Ruiz I, Serra E, Silvester JF, Mercader P, Sanchez J, Rodriguez M, Pastor A, Hervella M, Garcia I, Ortiz FJ. Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(3)DOI:10.1111/jdv.18595. PMID:36153692. IF:9,200 (Q1/1D). Document type: Letter.

-Van KR, Tzellos T, Alavi A, Benhadou F, Cuenca C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos EJ, Guillem P, Gulliver W, Jemec GBE, Katoulis A, Koenig A, Lazaridou E, Lowes MA, Marzano AV, Matusiak L, Molina A, Moltrasio C, Pinter A, Potenza C, Prens EP, Romaní J, Saunte DM, Sayed C, Skroza N, Stergianou D, Szepietowski JC, Trigoni A, Vilarrasa E, Kyrgidis A, Zouboulis CC, Van Der Zee HH. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort. DERMATOLOGY. 2023; 239(3)DOI:10.1159/000528968. PMID:36630943. IF:3,400 (Q2/3D). Document type: Article.

-Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Fosse N, Gáspár K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Rehbinder EM, Ring J, Rossi M, Roxburgh C, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. First update of the living European guideline (EuroGuiDerm) on atopic eczema. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(11):e1283-e1287. DOI:10.1111/jdv.19269. PMID:37328919. IF:9,200 (Q1/1D). Document type: Letter.

-Yélamos O, Andersen D, Pont M, Iglesias P, Potrony M, Domínguez M, Herrero A, Alejo B, Mateu J, Røpke M, Danneskiold NB, Malvehy J, Guy RH, Brix S, Puig S. Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(2)DOI:10.1093/ced/llac040. PMID:36730521. IF:4,100 (Q1/2D). Document type: Article.

-Yélamos O, Geller S, Tokez S. Skin cancer special issue in Skin Health and Disease. Skin Health And Disease. 2023; 3(2):e224. DOI:10.1002/ski2.224. PMID:37013119. Document type: Editorial Material.

-Yosipovitch G, Lio PA, Rosmarin D, Serra E, Legat FJ, Casillas M, Pierce E, Liu ZQ, Sun LN, Elmaraghy H, Ständer S. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; DOI:10.1093/bjd/ljad435. PMID:37939793. IF:10,300 (Q1/1D). Document type: Letter.

-Zabotti A, De Marco G, Gosset L, Baraliakos X, Aletaha D, Iagnocco A, Gisondi P, Balint PV, Bertheussen H, Boehncke WH, Damjanov NS, de Wit M, Errichetti E, Marzo H, Protopopov M, Puig L, Queiro R, Ruscitti P, Savage L, Schett G, Siebert S, Stamm TA, Studenic P, Tinazzi I, Van den Bosch FE, van der Helm A, Watad A, Smolen JS, McGonagle DG. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. ANNALS OF THE RHEUMATIC DISEASES. 2023; 82(9)DOI:10.1136/ard-2023-224148. PMID:37295926. IF:27,400 (Q1/1D). Document type: Article.

-Zuberbier T, Abdul A, Aggelidis X, Augustin M, Balan RG, Bangert C, Beck L, Bieber T, Bernstein JA, Bertolin M, Berardi A, Bedbrook A, Bindslev C, Bousquet J, de Bruin M, Bruscky D, Buyuktiryaki B, Canonica GW, Castro C, Chanturidze N, Chong HJ, Chu CY, Chularojanamontri L, Cork M, Criado RFJ, Barredo LC, Custovic A, Darsow U, Emurlai A, de Pablo A, Del Giacco S, Girolomoni G, Deleva T, Deleuran M, Douladiris N, Duarte B, Dubakiene R, Eller E, Engel B, Ensina LF, Filho NR, Flohr C, Fomina D, Francuzik W, Galimberti ML, Giménez AM, Godse K, Mortz CG, Gotua M, Hide M, Hoetzenecker W, Hunzelmann N, Irvine A, Jack C, Kanavarou I, Katoh N, Kinaciyan T, Kocatürk E, Kulthanan K, Lapeere H, Lau S, Machado Forti Nastri M, Makris M, Mansour E, Marsland A, Morelo Rocha Felix M, Moschione AP, Nettis E, Nicolas JF, Nosbaum A, Odemyr M, Papapostolou N, Parisi C, Paudel S, Peter J, Pokharel P, Puig L, Quint T, Ramon GD, Regateiro F, Ricci G, Rosario C, Sackesen C, Schmid P, Serra E, Siemens K, Smith C, Staubach P, Stevanovic K, Su Ö, Sussman G, Tavecchio S, Teovska N, Thaci D, Toubi E, Traidl C, Treudler R, Vadasz Z, van I, Ventura MT, Wang Z, Werfel T, Wollenberg A, Yang A, Weng Y, Zhao Z, Zwiener R, Worm M. A concept for integrated care pathways for atopic dermatitis-A GA(2) LEN ADCARE initiative. Clinical and Translational Allergy. 2023; 13(9):e12299. DOI:10.1002/clt2.12299. PMID:37746794. IF:4,400 (Q2/5D). Document type: Review.

Publications 2022

(JIF 2022)

Amat V, Lopez C, Tubau C, Puig L, Serra E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. CONTACT DERMATITIS. 2022; 87(1). DOI:10.1111/cod.14101. PMID:35277988. IF:5,5 (Q1/1D). Document Type: Editorial material.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2022; 12(12). DOI:10.1007/s13555-022-00812-z. PMID:36271222. IF:3,4 (Q2/3D). Document Type: Letter.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3,4 (Q2/3D). Document Type: Article.
Bechman K, Cook ES, Dand N, Yiu ZZN, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Meglio PD, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Smith CH, Galloway JB, Mahil SK, PsoProtect G. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2). DOI:10.1111/bjd.21042. PMID:35104366. IF:10,3 (Q1/1D). Document Type: Letter.
Bes M, Costafreda MI, Riveiro M, Piron M, Rico A, Quer J, Puig L, Sauleda S. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020. EMERGING INFECTIOUS DISEASES. 2022; 28(1). DOI:10.3201/eid2801.211466. PMID:34932460. IF:11,8 (Q1/1D). Document Type: Article.
Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4). DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13,8 (Q1/1D). Document Type: Article.
Canal E, Bosch X, Belinchon I, Puig L. Nail Psoriasis. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.006. PMID:35697407. Document Type: Review.
Carmona E, Iznardo H, Puig L. Retiform purpura in an 80-year-old woman. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2022; 61(10). DOI:10.1111/ijd.16120. PMID:35106756. IF:3,6 (Q1/3D). Document Type: Editorial material.
Carrascosa JM, Puig L, Romero IB, Salgado L, del Alcazar E, Lencina J, Moreno D, de la Cueva P. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermo-Sifiliograficas. 2022; 113(6):T583-T609. DOI:10.1016/j.ad.2022.01.024. PMID:35748004. Document type: Article/Practice Guideline.
Catala A, Munoz C, Galvan C, Riesco MR, Nebreda DR, Sola A, Giavedoni P, Llamas M, Gonzalez C, Cubiro X, Ruiz R, Gomez S, Mateo MPG, Pesque D, Marcantonio O, Fernandez D, Romani J, Pena NI, Gonzalez LC, Tercedor J, Carretero G, Masat T, Rodriguez P, Gimenez AM, Utrera M, Laguna EV, Menendez A, Lasser ES, Iglesias M, Naranjo LA, Hiltun I, Marco EC, Olabarrieta IP, Escobedo SM, Garcia X, Gutierrez MJC, Baeza G, Camps LB, Toledo T, Guilabert A. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(1). DOI:10.1111/bjd.20639. PMID:34254291. IF:10,3 (Q1/1D). Document Type: Article.
Chabra S, Gill BJ, Gallo G, Zhu DT, Pitou C, Payne CD, Accioly A, Puig L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6). DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3,8 (Q2/4D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Acosta EH, Vidal D, Vilarrasa E, Rivera R, De P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Rodriguez OB, Feltes R, Riera J, Dauden E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12):e15929. DOI:10.1111/dth.15929. PMID:36223184. IF:3,6 (Q1/3D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Herrera E, Vidal D, Vilarrasa E, Rivera R, De la Cueva P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Baniandres O, Feltes R, Alsina M, Dauden E. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy. 2022; 35(8):e15653. DOI:10.1111/dth.15653. PMID:35731640. IF:3,6 (Q1/3D). Document Type: Article.
Colmenero M, del Boz J, Wittel JB, Roe E, Feito M, Vicente MA, Martin A, Perez S, Azon A, Valdivielso M, Torrelo A, Moya A, Campos M, Garnacho G, Defez J, Casano AV, Tercedor J, Alcala R, Gonzalez MA, Giacaman A, Hernandez A, Garcia MTM, Bauza A, Dominguez J, Garcia I, Grau M. Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain. PEDIATRIC DERMATOLOGY. 2022; 39(4). DOI:10.1111/pde.15015. PMID:35504688. IF:1,5 (Q4/8D). Document Type: Article.
Cubiro X, Garcia C, Tubau C, Puig L. Nodular scabies mimicking breast cancer skin metastasis. Indian Journal of Dermatology Venereology & Leprology. 2022; 88(1). DOI:10.25259/IJDVL_63_2021. PMID:34623049. IF:2,9 (Q2/4D). Document Type: Letter.
de Bruin MS, Serra E, Barbarot S, Grond S, Schuster C, Petto H, Capron JP, Raibouaa A, Werfel T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6). DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3,4 (Q2/3D). Document Type: Article.
de Frutos JO, Carretero G, de Lucas R, Puig S, Serra E, Castro SG, Laserna FR, Loza E, Silvestre JF. Comorbidity identification and referral in atopic dermatitis: a consensus document. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(5). DOI:10.1080/09546634.2022.2067815. PMID:35435103. IF:2,9 (Q2/4D). Document Type: Article.
del Alcazar E, Lopez A, Martinez A, Julia M, Ruiz R, Fernandez LR, Notario J, Llamas M, Ferran M, Carrascosa JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6). DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2,9 (Q2/4D). Document Type: Letter.
del Alcazar E, Lopez A, Martinez A, Ruiz R, Llamas MD, Rocamora V, Julia M, Notario J, Fernandez LR, Sahuquillo A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P, Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2):e15231. DOI:10.1111/dth.15231. PMID:34820971. IF:3,6 (Q1/3D). Document Type: Article.
Fernandez A, Ballart C, Munoz J, Basarte L, Lobato G, Arnau A, Abras A, Tebar S, Llovet T, Lami P, Pratlong F, Alsina M, Roe E, Puig L, Munoz C, Gallego M. Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. Transboundary and Emerging Diseases. 2022; 69(3). DOI:10.1111/tbed.14107. PMID:33864706. IF:4,3 (Q1/1D). Document Type: Article.
Fernandez MT, Carrato C, Saenz X, Musulen E, Fuente MJ, Puig L. MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin. ARCHIVES OF DERMATOLOGICAL RESEARCH. 2022; 314(8). DOI:10.1007/s00403-021-02288-x. PMID:34647185. IF:3 (Q2/4D). Document Type: Article.
Gamissans M, Giavedoni P, Roe E, Sanchez J, Quintana M, Garbayo P, Vidal D, Riera N, Lopez C, Romani J, Wortsman X. Multicentric Study on High-Frequency Ultrasound Characterization of Calcium Deposits in Dermal and Subcutaneous Calciphylaxis and Calcinosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2022; 41(8). DOI:10.1002/jum.15878. PMID:34755910. IF:2,3 (Q2/5D). Document Type: Article.
Gimenez A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, Munoz F, Pedraz J, Serra E, Tejedor M, Velasco M, Terradas P, Labrador M. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2022; 32(3). DOI:10.18176/jiaci.0661. PMID:33349612. IF:7,2 (Q1/2D). Document Type: Article.
Iznardo H, Bredrup C, Bernal S, Gladkauskas T, Mascaro JM, Roe E, Baselga E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4). DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2,8 (Q3/6D). Document Type: Article.
Iznardo H, Puig L. Beyond plaque psoriasis – pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4). DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5,1 (Q2/3D). Document Type: Review.
Iznardo H, Puig L. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(16):9479. DOI:10.3390/ijms23169479. PMID:36012744. IF:5,6 (Q1/3D). Document Type: Review.
Iznardo H, Vilarrasa E, Roe E, Puig L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18116. PMID:35353931. IF:9,2 (Q1/1D). Document Type: Letter.
Krueger J, Puig L, Thaci D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7,3 (Q1/1D). Document Type: Review.
Le AM, Puig L, Torres T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7,3 (Q1/1D). Document Type: Review.
Lebwohl M, Langley RG, Paul C, Puig L, Reich K, van de Kerkhof P, Wu HL, Richter S, Jardon S, Gisondi P. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00635-4. PMID:34704231. IF:3,4 (Q2/3D). Document Type: Article.
Lebwohl M, Soliman AM, Yang HB, Wang J, Freimark J, Puig L. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(4). DOI:10.1080/09546634.2021.1919287. PMID:33899655. IF:2,9 (Q2/4D). Document Type: Article.
Lopez A, Laiz A, Puig L. Psoriatic arthritis. MEDICINA CLINICA. 2022; 159(1). DOI:10.1016/j.medcli.2022.01.024. PMID:35525675. IF:3,9 (Q2/4D). Document Type: Review.
Lopez A, Vilarrasa E, Armesto S, Santos J, Galache C, Carretero G, Sahuquillo A, Salgado L, del Alcazar E, Gonzalez A, Martorell A, Rivera R, Mitxelena J, Mateu A, Belinchon I, Llamas M, Riera J, Lazaro A, Lopez JL, Gich I, Puig L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11):e15831. DOI:10.1111/dth.15831. PMID:36109488. IF:3,6 (Q1/3D). Document Type: Letter.
Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7,3 (Q1/1D). Document Type: Review.
Medina D, Riera P, Pages N, Masip M, Lopez A, Vilarrasa E, Puig L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3). DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2,4 (Q3/8D). Document Type: Article.
Medrano RM, Estebaranz JLL, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, De Eusebio E, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, De la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Ruiz V, Sanchez P, Botella R, Gonzalez B, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, REGESMOHS Spanish Registry Mohs SU. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study. Actas Dermo-Sifiliograficas. 2022; 113(5). DOI:10.1016/j.ad.2022.01.035. Document Type: Article.
Melé G, Serra E, Spertino J, Guilarte M, Ribó P, Lleonart R, Figueras I, Bonfill M, Depreux N, Sala A, Bielsa I, Baliu C, Sanmartín V, Garcia X, Expósito V, Garnica D, Diaz MC, Gómez S, Gich I, Giménez A. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(5). DOI:10.1684/ejd.2022.4334. PMID:36468733. IF:2,5 (Q2/5D). Document Type: Article.
Oro M, Gonzalez B, Sanmartin O, Garces JR, Rodriguez MA, Ruiz V, de Eusebio E, Minano R, Escutia B, Cortizas CF, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, de la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Vilarrasa E, Sanchez P, Lopez JL, Botella R, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, Florez A. Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(1). DOI:10.1111/jdv.17597. PMID:34374137. IF:9,2 (Q1/1D). Document Type: Letter.
Pereyra J-J, Herranz P, Figuras I, Perez B, Elosua M, Munera M, Melgosa J, Zaragoza V, Silvestre JF, Campos M, Guilabert A, Miquel J, Alcantara S, De La Cueva P, Serra E, Armario JC. Upadacitinib for the Treatment of Atopic Dermatitis in a Spanish Cohort – Real Life: Fifty-Two-Week Follow-up Results. Dermatitis. 2022; 33(6). DOI:10.1097/DER.0000000000000958. PMID:36125777. IF:5,2 (Q1/2D). Document Type: Letter.
Pinter A, Puig L, Schakel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18376. PMID:35766124. IF:9,2 (Q1/1D). Document Type: Article.
Piron M, Jane M, Ciruela P, Basile L, Martinez A, Puig L, Bes M, Sauleda S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5). DOI:10.2450/2022.0232-21. PMID:35175189. IF:3,7 (Q2/4D). Document Type: Article.
Piron M, Salvador F, Caballero E, Sanchez A, Bes M, Casamitjana N, Puig L, Molina I, Sauleda S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9):1975. DOI:10.3390/v14091975. PMID:36146780. IF:4,7 (Q2/5D). Document Type: Article.
Puig L, Costanzo A, Munoz EJ, Jazra M, Wegner S, Paul CF, Conrad C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(5). DOI:10.1111/bjd.20963. PMID:34939663. IF:10,3 (Q1/1D). Document Type: Review.
Puig L. Psoriasis treatment: no more room on the summit?. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(6). DOI:10.1111/bjd.21848. PMID:36065496. IF:10,3 (Q1/1D). Document Type: Editorial material.
Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3). DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2,9 (Q2/4D). Document Type: Article.
Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Saday KK, Warren RB. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18068. PMID:35279890. IF:9,2 (Q1/1D). Document Type: Article.
Reolid A, Armesto S, Sahuquillo A, Torres T, Feltes R, Vilarrasa E, Belincho I, de la Cueva P, Rodriguez L, Romero A, Vidal D, Coto P, Herrera E, Riera J, Salgado L, Llamas M, Dauden E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3). DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13,8 (Q1/1D). Document Type: Letter.
Reymundo A, Vilarrasa E, Baniandrés O, Rodríguez L, Feltes R, Llamas M, Daudén E. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(10). DOI:10.1111/jdv.18317. PMID:35689497. IF:9,2 (Q1/1D). Document Type: Letter.
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Trakatelli M, Puig L, Stratigos A, EADV Burden Skin Dis Project T. Prevalence of most common skin diseases in Europe: a population-based study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(7). DOI:10.1111/jdv.18050. PMID:35274366. IF:9,2 (Q1/1D). Document Type: Article.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:3,4 (Q2/3D). Document Type: Article.
Rusinol L, Camina G, Puig L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12). DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4,6 (Q2/3D). Document Type: Article.
Sánchez G, Puig L. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6). DOI:10.1016/j.piel.2021.06.020. Document Type: Article.
Sans L, Figueras I, Bonfill M, De Jesus C, Garcia I, Guilabert A, Curto L, Bertolin M, Ferran M, Serra E, Zalewska A, Wang YH, Howell MD, Pujol RM, Santamaria LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11). DOI:10.1111/all.15424. PMID:35773619. IF:12,4 (Q1/1D). Document Type: Letter.
Sanz C, Nomdedeu M, Pereira A, Sauleda S, Alonso R, Bes M, Brillembourg H, Garcia C, Millan A, Martinez N, Piron M, Puerta P, Puig L, Rico V, Soriano A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5). DOI:10.1111/trf.16863. PMID:35338710. IF:2,9 (Q3/7D). Document Type: Article.
Serra E, Santamaria LF, Silvestre JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7). DOI:10.1016/j.ad.2021.12.014. PMID:35842249. Document Type: Review.
Thaci D, Gerdes S, Du KG, Perrot JL, Puig L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10). DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3,4 (Q2/3D). Document Type: Article.
Thaci D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye JN, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2). DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3,4 (Q2/3D). Document Type: Article.
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova I, Arents BWM, Bauer A, Brans R, Cannavo A, Christoffers WA, Crépy M-N, Elsner P, Fartasch M, Filon FL, Giménez AM, Gonçalo M, Guzmán MG, Hamann CR, Hoetzenecker W, Johansen JD, John SM, Kunkeler ACM, Hadzavdic SL, Molin S, Nixon R, Oosterhaven JAF, Rustemeyer T, Serra E, Shah M, Simon D, Skudlik C, Spiewak R, Valiukeviciene S, Voorberg AN, Weisshaar E, Agner T. Guidelines for diagnosis, prevention, and treatment of hand eczema. CONTACT DERMATITIS. 2022; 86(5). DOI:10.1111/cod.14035. PMID:34971008. IF:5,5 (Q1/1D). Document Type: Article/Practice Guideline.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, del Alcazar E, Rull EV, Llamas M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7,3 (Q1/1D). Document Type: Article.
Tubau C, Cubiro X, Amat V, Garcia C, Puig L, Roe E. Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. Journal Of Ultrasound. 2022; 25(4). DOI:10.1007/s40477-022-00665-4. PMID:35397096. Document Type: Article.
Van AM, Menting SP, Gyulai R, Iversen L, Van Der Kraaij GE, Middelkamp MA, Warren RB, Spuls PI, Schejtman AA, Egeberg A, Firooz A, Kumar AS, Oakley A, Foulkes A, Ramos AMC, Fougerousse A-C, Carija A, Akman A, Horváth B, Fábos B, Matlock BH, Claréus BW, Castro C, Ferrándiz C, Correa CC, Marchesi C, Goujon C, Gonzalez C, Maldonado C, Hong C-H, et al. [Vilarrasa E, Puig L]. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology. 2022; 158(5). DOI:10.1001/jamadermatol.2022.0434. PMID:35353175. IF:10,9 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9). DOI:10.1111/jdv.18345. PMID:35980214. IF:9,2 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18429. PMID:36056736. IF:9,2 (Q1/1D). Document Type: Article.
Zachariae C, Mrowietz U, Strodl J, Puig L. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4). DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2,5 (Q2/5D). Document Type: Article.
Zozaya N, Abdalla F, Zamora SA, Filgueiras JB, Carrillo JMC, Sanchez OD, Sinisterra FD, Garcia A, Pinto PH, Manfredi A, Olmos JM, Luna PMD, Puig L, Ros S, HIdalgo A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6). DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2,3 (Q3/7D). Document Type: Article.
Zozaya N, Villoro R, Abdalla F, Alfonso S, Balea J, Carrascosa JM, Delgado O, Dolz F, Garcia A, Herranz P, Manfredi A, Martinez J, Morales De los Rios Luna P, Puig L, Ros S, Hildago A. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. ACTA DERMATO-VENEREOLOGICA. 2022; 102:adv00678. DOI:10.2340/actadv.v102.583. PMID:35312022. IF:3,6 (Q1/3D). Document Type: Article.

Publications 2021

Amat V, Agut E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211055920. DOI:10.1177/20406223211055920. PMID:34840709. IF:4,970.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Puig L, Augustin M. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00511-1. PMID:33788177. IF:3,661.
Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, Gisondi P, Gooderham M, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Puig L. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(4). DOI:10.1111/jdv.17075. PMID:33533553. IF:9,228.
Buhl T, Rosmarin D, Serra E, Fernandez P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00534-8. PMID:33899152. IF:3,661.
Campos MC, Tubau C, Segura S, Gonzalez M, Iglesias M, Fernandez MT, Garcia MP, Mozos A. Oral submucous fibrosis presenting with histopathological lichenoid changes as predominant feature: Report of five cases and review of the literature. JOURNAL OF CUTANEOUS PATHOLOGY. 2021; 48(11). DOI:10.1111/cup.14084. PMID:34151457. IF:1,458.
Carretero G, Carrascosa JM, Puig L, Sánchez-Carazo JL, López-Ferrer A, Cueva P, Soria C, Rivera R, Belinchón I; Psoriasis Group of the Spanish Academy of Dermatology, Venereology. Definition of minimal disease activity in psoriasis. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(2):422-430. DOI:10.1111/jdv.16564. PMID: 32367536. IF:9,228.
Cubiro X, Garcia C, Morales CE, Roe E, Riera A, Mora JM, Iriarte A, Puig L, Baselga E. Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet. Dermatologic Therapy. 2021; 34(6):e15124. DOI:10.1111/dth.15124. PMID:34486206. IF:3,858.
de Bruin M, Merola JF, Hong CH, Baldrich ES, Ettler K, Sierka D, Delevry D, Chen Z, Rossi AB. Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective. Dermatology and Therapy. 2021; 11(6). DOI:10.1007/s13555-021-00621-w. PMID:34767181. IF:3,661.
Galvan C, Mitja O, Esteban S, Kafulafula J, Phiri T, Navarro I, Roman C, Mtenje H, Thauzeni G, Harawa E, Kaluzi S, Diere M, Mkandawire M, Malizani S, Chifundo A, Utrera M, Roncero M, Martin SL, Vilanova I, Petiti GH, Aranda MVD, Perez NN, Gomez MR, Iranzo P, Garcia PE, De Troya M, Gomez JR, Cardenoso E, Truyols SL, Unanue LA, et al. [Cubiro X, Lopez C]. A facility and community-based assessment of scabies in rural Malawi. PLoS Neglected Tropical Diseases. 2021; 15(6):e0009386. DOI:10.1371/journal.pntd.0009386. PMID:34061851. IF:4,781.
Garcia C, Roe E, Rodriguez B, Amat V, Cubiro X, Puig L, Boronat S. A case report of PHF6 mosaicism: Beyond the classic Borjeson-Forssman-Lehmann syndrome. PEDIATRIC DERMATOLOGY. 2021; 38(4). DOI:10.1111/pde.14636. PMID:34041787. IF:1,997.
Garcia J, Delgadillo J, Vilarrodona A, Querol S, Ovejo J, Coll R, Millan A, Madrigal A, Soria G, Vidal F, Vives J, Herrero MJ, Lopez I, Sauleda S, Contreras E, Grifols JR, Guasch R, Tahull E, Puig L, Masip A, Argelagues E, Muniz E. SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfusion. 2021; 19(2). DOI:10.2450/2021.0259-20. PMID:33539280. IF:5,752.
García-Martínez FJ, Vilarrasa E, Salgado-Boquete L, Martorell A, Pascual JC, Hernández-Martín Á, Silvente C, Ciudad-Blanco C, Andrés Esteban E, Alfageme-Roldán F. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021y;32(3):286-290. DOI:10.1080/09546634.2019.1655524. PMID: 31402725. IF:3,230.
Girolomoni G, de Bruin M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB. Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211002979. DOI:10.1177/20406223211002979. PMID:33854747. IF:4,970.
Gomis-Pastor M, Mirabet Perez S, Roig Minguell E, Brossa Loidi V, Lopez Lopez L, Ros Abarca S, Galvez Tugas E, Mas-Malagarriga N, Mangues Bafalluy MA. Mobile Health to Improve Adherence and Patient Experience in Heart Transplantation Recipients: The mHeart Trial. Healthcare (Basel). 2021;9(4):463. DOI:10.3390/healthcare9040463. PMID: 33919899. IF:3,160.
González-Manso A, Agut-Busquet E, Romaní J, Vilarrasa E, Bittencourt F, Mensa A, Cantó E, Aróstegui JI, Vidal S. Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis. Dermatology. 2021;237(3):365-371. DOI:10.1159/000511045. PMID: 33171462. IF:5,197.
Iznardo H, Baselga E, Mozos A, Szafranska J, Orellana R, Roe E. Net-like superficial lymphatic malformation. PEDIATRIC DERMATOLOGY. 2021; 38(2). DOI:10.1111/pde.14526. PMID:33486776. IF:1,997.
Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211037846. DOI:10.1177/20406223211037846. PMID:34408825. IF:4,970.
Iznardo H, Puig L. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(9):4344. DOI:10.3390/ijms22094344. PMID:33919434. IF:6,208.
Iznardo H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Review of Clinical Immunology. 2021; 17(2). DOI:10.1080/1744666X.2021.1886081. PMID:33538202. IF:5,124.
Julia A, Martinez SH, Domenech E, Canete JD, Ferrandiz C, Tornero J, Gisbert JP, Fernandez A, Dauden E, Barreiro M, Perez C, Queiro R, Lopez FJ, Carazo JLS, Mendoza JL, Alperi M, Montilla C, Venegas JJP, Munoz F, Castaneda S, Lasanta ML, Marsal S, Fonseca E, Rodriguez J, Carreira P, Garcia V, Pinto JA, Puig L, Ricart E, Blanco F, Gratacos J, et al. [Garcia E, Diaz C]. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2021; 75(9). DOI:10.1038/s41430-021-00913-6. PMID:33893449. IF:4,884.
Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, Abuzakouk M, Agondi RC, Al-Ahmad M, Altrichter S, Arnaout R, Arruda LK, Asero R, Bauer A, Ben-Shoshan M, Bernstein JA, Bizjak M, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Busse P, Campos RA, Carne E, Conlon N, Criado RF, de Souza Lima EM, Demir S, et al. [Serra-Baldrich E]. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76(3):816-830. DOI:10.1111/all.14687. PMID: 33284457. IF:14,710.
Lambert J, Hansen JB, Sohrt A, Puig L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00545-5. PMID:33988818. IF:3,661.
Llao J, Masnou H, Romero C, Bargallo A, Gely C, Manosa M, Gordillo J, Garcia E, Domenech E. Noninvasive assessment of liver fibrosis in Crohn’s disease patients exposed to methotrexate. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 2021; 33(6). DOI:10.1097/MEG.0000000000001799. PMID:32804842. IF:2,586.
Lopez C, Falla LM, Roe E, Arostegui JI, Mozos A, Bernal S, Iznardo H, Baselga E. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. JOURNAL OF DERMATOLOGY. 2021; 48(6). DOI:10.1111/1346-8138.15673. PMID:33543522. IF:3,468.
Lopez C, Romani J, Garbayo P, Agut E. Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. JOURNAL OF DERMATOLOGY. 2021; 48(4). DOI:10.1111/1346-8138.15728. PMID:33547675. IF:3,468.
Lopez C, Romani J, Roe E, Giavedoni P, Vidal D, Wortsman X. Ultrasonographic patterns of cutaneous sarcoidosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2021; 40(11). DOI:10.1002/jum.15631. PMID:33459396. IF:2,754.
Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di P, Langan SM, Capon F, et al.; PsoProtect GRP. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2021; 147(1). DOI:10.1016/j.jaci.2020.10.007. PMID:33075408. IF:14,290.
Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, de la Cruz C, Di P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, et al.; PsoProtect CORE GRP. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(1). DOI:10.1111/bjd.19755. PMID:33368145. IF:11,113.
Marron SE, Gomez M, Aragones LT, Goni A, Vilarrasa E, Diaz RM, Garcia FJ, Campos R, Fuentelsaz V, Gilaberte Y, Gracia T, Morales AM, Ros S, Madrid MB, Puig L. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv00529. DOI:10.2340/00015555-3905. PMID:34427316. IF:3,875.
Massey PR, Schmults CD, Li SJ, Arron ST, Asgari MM, Bavinck JNB, Billingsley E, Blalock TW, Blasdale K, Carroll BT, Carucci JA, Chong AH, Christensen SR, Chung CL, DeSimone JA, Ducroux E, Escutia B, Ferrandiz C, Fox MC, Genders RE, Geusau A, Gjersvik P, Hanlon AM, Harken E, Hofbauer GFL, Hopkins RS, Leitenberger JJ, Loss MJ, Del Marmol V, et al. [Ruiz V]. Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients A Delphi Consensus Statement. JAMA Dermatology. 2021; 157(10). DOI:10.1001/jamadermatol.2021.3180. PMID:34468690. IF:11,816.
Mogedas A, Agut E, Marsal MY, Aguilar JL, de la Torre OE. Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. 2021; 79(12). DOI:10.1016/j.joms.2021.07.009. PMID:34391723. IF:2,136.
Muniz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, Millan A, Ene G, Ramiro L, Maglio L, Garcia N, Pinacho A, Jaramillo A, Pero A, Artaza G, Valles R, Sauleda S, Puig L, Contreras E. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfusion. 2021; 19(1). DOI:10.2450/2020.0256-20. PMID:33196417. IF:5,752.
Munoz FZ, Rios M, Roe E, Bernabeu J, Montserrat MT, Puig L, Gich I, Baselga E. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage A Randomized Clinical Trial. JAMA Dermatology. 2021; 157(5). DOI:10.1001/jamadermatol.2021.0596. PMID:33825828. IF:11,816.
Nieto LM, Ciudad C, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, de Eusebio E, Minano R, Escutia B, Gonzalez B, Artola JL, Rubio AA, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, Dobao PD, Navarro R, Suarez R, Carnero L, Vazquez H, Barchino L, Ruiz V, Sanchez P, Lopez JL, Botella R, Feal C, Calatayud AM, Gil P, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. EXPERIMENTAL DERMATOLOGY. 2021; 30(5). DOI:10.1111/exd.14291. PMID:33523531. IF:4,511.
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(6). DOI:10.1111/bjd.20595. PMID:34157132. IF:11,113.
Papp KA, Soliman AM, Done N, Carley C, Wirtz EL, Puig L. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00550-8. PMID:34019229. IF:3,661.
Pereira MP, Zeidler C, Wallengren J, Halvorsen JA, Weisshaar E, Garcovich S, Misery L, Brenaut E, Savk E, Potekaev N, Lvov A, Bobko S, Szepietowski JC, Reich A, Bozek A, Legat FJ, Metz M, Streit M, Serra E, Goncalo M, Storck M, Nau T, Hoffmann V, Steinke S, Greiwe I, Dugas M, Augustin M, Stander S, European Prurigo Project Epp C. Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv000403. DOI:10.2340/00015555-3726. PMID:33320272. IF:3,875.
Pereira MP, Ziehfreund S, Rueth M, Ewering T, Legat FJ, Lambert J, Elberling J, Misery L, Brenaut E, Papadavid E, Garcovich S, Evers A, Halvorsen JA, Szepietowski JC, Reich A, Goncalo M, Lvov A, Bobko S, Serra E, Wallengren J, Savk E, Leslie T, Stander S, Zink A, EADV Task Force P. Google search trends for itch in Europe: a retrospective longitudinal study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(6). DOI:10.1111/jdv.17077. PMID:33295009. IF:9,228.
Piquero-Casals J, Martínez-Martínez L, Alomar A, Rozas-Muñoz E, Juarez C, Puig L. LRP1/CD91 is highly expressed in monocytes from patients with vitiligo – even after repigmentation. Experimental Dermatology. 2021;30(3):390-395. DOI:10.1111/exd.14249. PMID: 33249636. IF:4,511.
Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, Zolkin NA, Kuryshev IV, Petrov AN, Artemeva AV, Zinkina AV. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00554-4. PMID:34060012. IF:3,661.
Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021;32(5):484-491. DOI:10.1080/09546634.2019.1679336. PMID: 31613178. IF:3,230.
Reich K, Hansen JB, Puig L, Konstantinou MP, Warren RB. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(10). DOI:10.1111/jdv.17433. PMID:34076919. IF:9,228.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Román E, Parramón M, Flavià M, Gely C, Poca M, Gallego A, Santesmases R, Hernández E, Nieto JC, Urgell E, Alvarado-Tapias E, Vidal S, Ferrero-Gregori A, Vargas V, Guarner C, Soriano G. Frailty in outpatients with cirrhosis: A prospective observational study. Liver International. 2021;41(2):357-368. DOI:10.1111/liv.14694. PMID: 33030788. IF:8,754.
Roman E, Poca M, Amoros G, Rosell J, Gely C, Nieto JC, Vidal S, Urgell E, Ferrero A, Alvarado E, Cuyas B, Hernandez E, Santesmases R, Guarner C, Escorsell A, Soriano G. Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Scientific Reports. 2021; 11(1):20415. DOI:10.1038/s41598-021-99199-8. PMID:34650096. IF:4,996.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:5,197.
Rusinol L, Amat V, Baselga E, Puig L, Roe E. Prepubertal retroareolar cysts. PEDIATRIC DERMATOLOGY. 2021; 38(5). DOI:10.1111/pde.14786. PMID:34514639. IF:1,997.
Salvador JFS, Gimenez AM, de la Fuente EG, del Castillo JG, Virto A, Blanco IM, Serra E, Llorens P. Managing urticaria in the emergency department: recommendations of a multidisciplinary expert panel. Emergencias. 2021; 33(4). PMID:34251143. IF:5,345.
Sanchez MJ, Docampo A, Mercader P, Gonzalez R, Hervella M, Sanz T, Cordoba S, Sanchez J, Heras F, Gimenez AM, Gatica ME, Pastor MA, Zaragoza V, Carrascosa JM, Garcia B, Ruiz I, Borrego L, Sanchez P, Frutos JO, Armario JC, Garcia J, Fernandez V, Serra E, Silvestre JF. Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index. CONTACT DERMATITIS. 2021; 84(6). DOI:10.1111/cod.13801. PMID:33534191. IF:6,419.
Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. DRUGS IN R&D. 2021; 21(3). DOI:10.1007/s40268-021-00349-0. PMID:34106430. IF:3,203.
Storck M, Sandmann S, Bruland P, Pereira MP, Steinke S, Riepe C, Soto I, Garcovich S, Augustin M, Blome C, Bobko S, Legat FJ, Potekaev N, Lvov A, Misery L, Weger W, Reich A, Savk E, Streit M, Serra E, Szepietowski JC, Dugas M, Stander S, Zeidler C. Pruritus Intensity Scales across Europe: a prospective validation study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(5). DOI:10.1111/jdv.17111. PMID:33411947. IF:9,228.
Suppa M, Fontaine M, Dejonckheere G, Cinotti E, Yélamos O, Diet G, Tognetti L, Miyamoto M, Orte Cano C, Perez-Anker J, Panagiotou V, Trepant AL, Monnier J, Berot V, Puig S, Rubegni P, Malvehy J, Perrot JL, Del Marmol V. Line-field confocal optical coherence tomography of basal cell carcinoma: a descriptive study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(5):1099-1110. DOI:10.1111/jdv.17078. PMID: 33398911. IF:9,228.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Dauden E, Conrad C, Mendes P, Ferreira P, Leite L, Lu JSD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas M, del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung JN, Nogueira M, Chiricozzi A. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2021; 22(4). DOI:10.1007/s40257-021-00598-4. PMID:33786754. IF:6,233.
Tubau C, Puig L. IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy. 2021; 13(4). DOI:10.2217/imt-2020-0253. PMID:33430628. IF:4,040.
Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Review of Clinical Immunology. 2021;17(1):15-25. DOI:10.1080/1744666X.2020.1858802. PMID: 33275064. IF:5,124.
Valdivielso-Ramos M, Martin-Santiago A, Azaña JM, Hernández-Nuñez A, Vera A, Perez B, Tercedor J, Feito M, Vicente A, Prat C, Lopez-Gutierrez JC, Garnacho G, Baselga E, Roe E, Palencia S, Cordero P, Moreno R, Agudo A, de la Cueva P, Torrelo A. Capillary malformation-arteriovenous malformation syndrome: a multicentre study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2021;46(2):300-305. DOI:10.1111/ced.14428. PMID: 32840927. IF:4,481.
van KR, Tzellos T, Guillem P, Benhadou F, Cuenca C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos EJ, Jemec G, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak L, Molina A, Moltrasio C, Pinter A, Potenza C, Romani J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2021; 85(2). DOI:10.1016/j.jaad.2020.12.089. PMID:33484766. IF:15,487.
Vidal S, Puig L, Carrascosa JM, Gonzalez A, Ruiz JC, Velasco AM. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(13):6740. DOI:10.3390/ijms22136740. PMID:34201664. IF:6,208.
Yélamos O, Alejo B, Ertekin SS, Villa-Crespo L, Zamora-Barquero S, Martinez N, Domínguez M, Iglesias P, Herrero A, Malvehy J, Puig S. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):143-149. DOI:10.1111/jdv.16559. PMID: 32365242. IF:9,228.

Introduction

Main lines of research

Biologic therapy in dermatology.
Genome-wide association studies in psoriasis.
Medical and physical treatment options for vascular tumours.
Psychopathological studies of patients with chronic dermatological disorders.
Innate and acquired immunologically-mediated dermatological.

Challenges

Ensure a stable clinical research infrastructure and staff.
Foster interdepartmental collaborative research.

Team

Group coordination

PUIG SANZ, LUIS FGS
lpuig@santpau.cat

Members

Scientific output

Publications 2023

(JIF 2022)

-Mateu L, Puig L. Genetic and Epigenetic Mechanisms of Psoriasis. Genes. 2023; 14(8):1619. DOI:10.3390/genes14081619. PMID:37628670. IF:3,500 (Q2/4D). Document type: Review.

-Yélamos O, Geller S, Tokez S. Skin cancer special issue in Skin Health and Disease. Skin Health And Disease. 2023; 3(2):e224. DOI:10.1002/ski2.224. PMID:37013119. Document type: Editorial Material.

Publications 2022

(JIF 2022)

Amat V, Lopez C, Tubau C, Puig L, Serra E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. CONTACT DERMATITIS. 2022; 87(1). DOI:10.1111/cod.14101. PMID:35277988. IF:5,5 (Q1/1D). Document Type: Editorial material.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2022; 12(12). DOI:10.1007/s13555-022-00812-z. PMID:36271222. IF:3,4 (Q2/3D). Document Type: Letter.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3,4 (Q2/3D). Document Type: Article.
Bechman K, Cook ES, Dand N, Yiu ZZN, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Meglio PD, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Smith CH, Galloway JB, Mahil SK, PsoProtect G. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2). DOI:10.1111/bjd.21042. PMID:35104366. IF:10,3 (Q1/1D). Document Type: Letter.
Bes M, Costafreda MI, Riveiro M, Piron M, Rico A, Quer J, Puig L, Sauleda S. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020. EMERGING INFECTIOUS DISEASES. 2022; 28(1). DOI:10.3201/eid2801.211466. PMID:34932460. IF:11,8 (Q1/1D). Document Type: Article.
Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4). DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13,8 (Q1/1D). Document Type: Article.
Canal E, Bosch X, Belinchon I, Puig L. Nail Psoriasis. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.006. PMID:35697407. Document Type: Review.
Carmona E, Iznardo H, Puig L. Retiform purpura in an 80-year-old woman. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2022; 61(10). DOI:10.1111/ijd.16120. PMID:35106756. IF:3,6 (Q1/3D). Document Type: Editorial material.
Carrascosa JM, Puig L, Romero IB, Salgado L, del Alcazar E, Lencina J, Moreno D, de la Cueva P. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermo-Sifiliograficas. 2022; 113(6):T583-T609. DOI:10.1016/j.ad.2022.01.024. PMID:35748004. Document type: Article/Practice Guideline.
Catala A, Munoz C, Galvan C, Riesco MR, Nebreda DR, Sola A, Giavedoni P, Llamas M, Gonzalez C, Cubiro X, Ruiz R, Gomez S, Mateo MPG, Pesque D, Marcantonio O, Fernandez D, Romani J, Pena NI, Gonzalez LC, Tercedor J, Carretero G, Masat T, Rodriguez P, Gimenez AM, Utrera M, Laguna EV, Menendez A, Lasser ES, Iglesias M, Naranjo LA, Hiltun I, Marco EC, Olabarrieta IP, Escobedo SM, Garcia X, Gutierrez MJC, Baeza G, Camps LB, Toledo T, Guilabert A. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(1). DOI:10.1111/bjd.20639. PMID:34254291. IF:10,3 (Q1/1D). Document Type: Article.
Chabra S, Gill BJ, Gallo G, Zhu DT, Pitou C, Payne CD, Accioly A, Puig L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6). DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3,8 (Q2/4D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Acosta EH, Vidal D, Vilarrasa E, Rivera R, De P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Rodriguez OB, Feltes R, Riera J, Dauden E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12):e15929. DOI:10.1111/dth.15929. PMID:36223184. IF:3,6 (Q1/3D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Herrera E, Vidal D, Vilarrasa E, Rivera R, De la Cueva P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Baniandres O, Feltes R, Alsina M, Dauden E. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy. 2022; 35(8):e15653. DOI:10.1111/dth.15653. PMID:35731640. IF:3,6 (Q1/3D). Document Type: Article.
Colmenero M, del Boz J, Wittel JB, Roe E, Feito M, Vicente MA, Martin A, Perez S, Azon A, Valdivielso M, Torrelo A, Moya A, Campos M, Garnacho G, Defez J, Casano AV, Tercedor J, Alcala R, Gonzalez MA, Giacaman A, Hernandez A, Garcia MTM, Bauza A, Dominguez J, Garcia I, Grau M. Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain. PEDIATRIC DERMATOLOGY. 2022; 39(4). DOI:10.1111/pde.15015. PMID:35504688. IF:1,5 (Q4/8D). Document Type: Article.
Cubiro X, Garcia C, Tubau C, Puig L. Nodular scabies mimicking breast cancer skin metastasis. Indian Journal of Dermatology Venereology & Leprology. 2022; 88(1). DOI:10.25259/IJDVL_63_2021. PMID:34623049. IF:2,9 (Q2/4D). Document Type: Letter.
de Bruin MS, Serra E, Barbarot S, Grond S, Schuster C, Petto H, Capron JP, Raibouaa A, Werfel T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6). DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3,4 (Q2/3D). Document Type: Article.
de Frutos JO, Carretero G, de Lucas R, Puig S, Serra E, Castro SG, Laserna FR, Loza E, Silvestre JF. Comorbidity identification and referral in atopic dermatitis: a consensus document. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(5). DOI:10.1080/09546634.2022.2067815. PMID:35435103. IF:2,9 (Q2/4D). Document Type: Article.
del Alcazar E, Lopez A, Martinez A, Julia M, Ruiz R, Fernandez LR, Notario J, Llamas M, Ferran M, Carrascosa JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6). DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2,9 (Q2/4D). Document Type: Letter.
del Alcazar E, Lopez A, Martinez A, Ruiz R, Llamas MD, Rocamora V, Julia M, Notario J, Fernandez LR, Sahuquillo A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P, Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2):e15231. DOI:10.1111/dth.15231. PMID:34820971. IF:3,6 (Q1/3D). Document Type: Article.
Fernandez A, Ballart C, Munoz J, Basarte L, Lobato G, Arnau A, Abras A, Tebar S, Llovet T, Lami P, Pratlong F, Alsina M, Roe E, Puig L, Munoz C, Gallego M. Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. Transboundary and Emerging Diseases. 2022; 69(3). DOI:10.1111/tbed.14107. PMID:33864706. IF:4,3 (Q1/1D). Document Type: Article.
Fernandez MT, Carrato C, Saenz X, Musulen E, Fuente MJ, Puig L. MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin. ARCHIVES OF DERMATOLOGICAL RESEARCH. 2022; 314(8). DOI:10.1007/s00403-021-02288-x. PMID:34647185. IF:3 (Q2/4D). Document Type: Article.
Gamissans M, Giavedoni P, Roe E, Sanchez J, Quintana M, Garbayo P, Vidal D, Riera N, Lopez C, Romani J, Wortsman X. Multicentric Study on High-Frequency Ultrasound Characterization of Calcium Deposits in Dermal and Subcutaneous Calciphylaxis and Calcinosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2022; 41(8). DOI:10.1002/jum.15878. PMID:34755910. IF:2,3 (Q2/5D). Document Type: Article.
Gimenez A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, Munoz F, Pedraz J, Serra E, Tejedor M, Velasco M, Terradas P, Labrador M. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2022; 32(3). DOI:10.18176/jiaci.0661. PMID:33349612. IF:7,2 (Q1/2D). Document Type: Article.
Iznardo H, Bredrup C, Bernal S, Gladkauskas T, Mascaro JM, Roe E, Baselga E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4). DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2,8 (Q3/6D). Document Type: Article.
Iznardo H, Puig L. Beyond plaque psoriasis – pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4). DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5,1 (Q2/3D). Document Type: Review.
Iznardo H, Puig L. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(16):9479. DOI:10.3390/ijms23169479. PMID:36012744. IF:5,6 (Q1/3D). Document Type: Review.
Iznardo H, Vilarrasa E, Roe E, Puig L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18116. PMID:35353931. IF:9,2 (Q1/1D). Document Type: Letter.
Krueger J, Puig L, Thaci D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7,3 (Q1/1D). Document Type: Review.
Le AM, Puig L, Torres T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7,3 (Q1/1D). Document Type: Review.
Lebwohl M, Langley RG, Paul C, Puig L, Reich K, van de Kerkhof P, Wu HL, Richter S, Jardon S, Gisondi P. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00635-4. PMID:34704231. IF:3,4 (Q2/3D). Document Type: Article.
Lebwohl M, Soliman AM, Yang HB, Wang J, Freimark J, Puig L. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(4). DOI:10.1080/09546634.2021.1919287. PMID:33899655. IF:2,9 (Q2/4D). Document Type: Article.
Lopez A, Laiz A, Puig L. Psoriatic arthritis. MEDICINA CLINICA. 2022; 159(1). DOI:10.1016/j.medcli.2022.01.024. PMID:35525675. IF:3,9 (Q2/4D). Document Type: Review.
Lopez A, Vilarrasa E, Armesto S, Santos J, Galache C, Carretero G, Sahuquillo A, Salgado L, del Alcazar E, Gonzalez A, Martorell A, Rivera R, Mitxelena J, Mateu A, Belinchon I, Llamas M, Riera J, Lazaro A, Lopez JL, Gich I, Puig L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11):e15831. DOI:10.1111/dth.15831. PMID:36109488. IF:3,6 (Q1/3D). Document Type: Letter.
Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7,3 (Q1/1D). Document Type: Review.
Medina D, Riera P, Pages N, Masip M, Lopez A, Vilarrasa E, Puig L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3). DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2,4 (Q3/8D). Document Type: Article.
Medrano RM, Estebaranz JLL, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, De Eusebio E, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, De la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Ruiz V, Sanchez P, Botella R, Gonzalez B, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, REGESMOHS Spanish Registry Mohs SU. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study. Actas Dermo-Sifiliograficas. 2022; 113(5). DOI:10.1016/j.ad.2022.01.035. Document Type: Article.
Melé G, Serra E, Spertino J, Guilarte M, Ribó P, Lleonart R, Figueras I, Bonfill M, Depreux N, Sala A, Bielsa I, Baliu C, Sanmartín V, Garcia X, Expósito V, Garnica D, Diaz MC, Gómez S, Gich I, Giménez A. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(5). DOI:10.1684/ejd.2022.4334. PMID:36468733. IF:2,5 (Q2/5D). Document Type: Article.
Oro M, Gonzalez B, Sanmartin O, Garces JR, Rodriguez MA, Ruiz V, de Eusebio E, Minano R, Escutia B, Cortizas CF, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, de la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Vilarrasa E, Sanchez P, Lopez JL, Botella R, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, Florez A. Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(1). DOI:10.1111/jdv.17597. PMID:34374137. IF:9,2 (Q1/1D). Document Type: Letter.
Pereyra J-J, Herranz P, Figuras I, Perez B, Elosua M, Munera M, Melgosa J, Zaragoza V, Silvestre JF, Campos M, Guilabert A, Miquel J, Alcantara S, De La Cueva P, Serra E, Armario JC. Upadacitinib for the Treatment of Atopic Dermatitis in a Spanish Cohort – Real Life: Fifty-Two-Week Follow-up Results. Dermatitis. 2022; 33(6). DOI:10.1097/DER.0000000000000958. PMID:36125777. IF:5,2 (Q1/2D). Document Type: Letter.
Pinter A, Puig L, Schakel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18376. PMID:35766124. IF:9,2 (Q1/1D). Document Type: Article.
Piron M, Jane M, Ciruela P, Basile L, Martinez A, Puig L, Bes M, Sauleda S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5). DOI:10.2450/2022.0232-21. PMID:35175189. IF:3,7 (Q2/4D). Document Type: Article.
Piron M, Salvador F, Caballero E, Sanchez A, Bes M, Casamitjana N, Puig L, Molina I, Sauleda S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9):1975. DOI:10.3390/v14091975. PMID:36146780. IF:4,7 (Q2/5D). Document Type: Article.
Puig L, Costanzo A, Munoz EJ, Jazra M, Wegner S, Paul CF, Conrad C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(5). DOI:10.1111/bjd.20963. PMID:34939663. IF:10,3 (Q1/1D). Document Type: Review.
Puig L. Psoriasis treatment: no more room on the summit?. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(6). DOI:10.1111/bjd.21848. PMID:36065496. IF:10,3 (Q1/1D). Document Type: Editorial material.
Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3). DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2,9 (Q2/4D). Document Type: Article.
Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Saday KK, Warren RB. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18068. PMID:35279890. IF:9,2 (Q1/1D). Document Type: Article.
Reolid A, Armesto S, Sahuquillo A, Torres T, Feltes R, Vilarrasa E, Belincho I, de la Cueva P, Rodriguez L, Romero A, Vidal D, Coto P, Herrera E, Riera J, Salgado L, Llamas M, Dauden E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3). DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13,8 (Q1/1D). Document Type: Letter.
Reymundo A, Vilarrasa E, Baniandrés O, Rodríguez L, Feltes R, Llamas M, Daudén E. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(10). DOI:10.1111/jdv.18317. PMID:35689497. IF:9,2 (Q1/1D). Document Type: Letter.
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Trakatelli M, Puig L, Stratigos A, EADV Burden Skin Dis Project T. Prevalence of most common skin diseases in Europe: a population-based study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(7). DOI:10.1111/jdv.18050. PMID:35274366. IF:9,2 (Q1/1D). Document Type: Article.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:3,4 (Q2/3D). Document Type: Article.
Rusinol L, Camina G, Puig L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12). DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4,6 (Q2/3D). Document Type: Article.
Sánchez G, Puig L. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6). DOI:10.1016/j.piel.2021.06.020. Document Type: Article.
Sans L, Figueras I, Bonfill M, De Jesus C, Garcia I, Guilabert A, Curto L, Bertolin M, Ferran M, Serra E, Zalewska A, Wang YH, Howell MD, Pujol RM, Santamaria LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11). DOI:10.1111/all.15424. PMID:35773619. IF:12,4 (Q1/1D). Document Type: Letter.
Sanz C, Nomdedeu M, Pereira A, Sauleda S, Alonso R, Bes M, Brillembourg H, Garcia C, Millan A, Martinez N, Piron M, Puerta P, Puig L, Rico V, Soriano A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5). DOI:10.1111/trf.16863. PMID:35338710. IF:2,9 (Q3/7D). Document Type: Article.
Serra E, Santamaria LF, Silvestre JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7). DOI:10.1016/j.ad.2021.12.014. PMID:35842249. Document Type: Review.
Thaci D, Gerdes S, Du KG, Perrot JL, Puig L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10). DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3,4 (Q2/3D). Document Type: Article.
Thaci D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye JN, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2). DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3,4 (Q2/3D). Document Type: Article.
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova I, Arents BWM, Bauer A, Brans R, Cannavo A, Christoffers WA, Crépy M-N, Elsner P, Fartasch M, Filon FL, Giménez AM, Gonçalo M, Guzmán MG, Hamann CR, Hoetzenecker W, Johansen JD, John SM, Kunkeler ACM, Hadzavdic SL, Molin S, Nixon R, Oosterhaven JAF, Rustemeyer T, Serra E, Shah M, Simon D, Skudlik C, Spiewak R, Valiukeviciene S, Voorberg AN, Weisshaar E, Agner T. Guidelines for diagnosis, prevention, and treatment of hand eczema. CONTACT DERMATITIS. 2022; 86(5). DOI:10.1111/cod.14035. PMID:34971008. IF:5,5 (Q1/1D). Document Type: Article/Practice Guideline.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, del Alcazar E, Rull EV, Llamas M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7,3 (Q1/1D). Document Type: Article.
Tubau C, Cubiro X, Amat V, Garcia C, Puig L, Roe E. Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. Journal Of Ultrasound. 2022; 25(4). DOI:10.1007/s40477-022-00665-4. PMID:35397096. Document Type: Article.
Van AM, Menting SP, Gyulai R, Iversen L, Van Der Kraaij GE, Middelkamp MA, Warren RB, Spuls PI, Schejtman AA, Egeberg A, Firooz A, Kumar AS, Oakley A, Foulkes A, Ramos AMC, Fougerousse A-C, Carija A, Akman A, Horváth B, Fábos B, Matlock BH, Claréus BW, Castro C, Ferrándiz C, Correa CC, Marchesi C, Goujon C, Gonzalez C, Maldonado C, Hong C-H, et al. [Vilarrasa E, Puig L]. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology. 2022; 158(5). DOI:10.1001/jamadermatol.2022.0434. PMID:35353175. IF:10,9 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9). DOI:10.1111/jdv.18345. PMID:35980214. IF:9,2 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18429. PMID:36056736. IF:9,2 (Q1/1D). Document Type: Article.
Zachariae C, Mrowietz U, Strodl J, Puig L. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4). DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2,5 (Q2/5D). Document Type: Article.
Zozaya N, Abdalla F, Zamora SA, Filgueiras JB, Carrillo JMC, Sanchez OD, Sinisterra FD, Garcia A, Pinto PH, Manfredi A, Olmos JM, Luna PMD, Puig L, Ros S, HIdalgo A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6). DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2,3 (Q3/7D). Document Type: Article.
Zozaya N, Villoro R, Abdalla F, Alfonso S, Balea J, Carrascosa JM, Delgado O, Dolz F, Garcia A, Herranz P, Manfredi A, Martinez J, Morales De los Rios Luna P, Puig L, Ros S, Hildago A. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. ACTA DERMATO-VENEREOLOGICA. 2022; 102:adv00678. DOI:10.2340/actadv.v102.583. PMID:35312022. IF:3,6 (Q1/3D). Document Type: Article.

Publications 2021

Amat V, Agut E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211055920. DOI:10.1177/20406223211055920. PMID:34840709. IF:4,970.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Puig L, Augustin M. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00511-1. PMID:33788177. IF:3,661.
Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, Gisondi P, Gooderham M, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Puig L. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(4). DOI:10.1111/jdv.17075. PMID:33533553. IF:9,228.
Buhl T, Rosmarin D, Serra E, Fernandez P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00534-8. PMID:33899152. IF:3,661.
Campos MC, Tubau C, Segura S, Gonzalez M, Iglesias M, Fernandez MT, Garcia MP, Mozos A. Oral submucous fibrosis presenting with histopathological lichenoid changes as predominant feature: Report of five cases and review of the literature. JOURNAL OF CUTANEOUS PATHOLOGY. 2021; 48(11). DOI:10.1111/cup.14084. PMID:34151457. IF:1,458.
Carretero G, Carrascosa JM, Puig L, Sánchez-Carazo JL, López-Ferrer A, Cueva P, Soria C, Rivera R, Belinchón I; Psoriasis Group of the Spanish Academy of Dermatology, Venereology. Definition of minimal disease activity in psoriasis. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(2):422-430. DOI:10.1111/jdv.16564. PMID: 32367536. IF:9,228.
Cubiro X, Garcia C, Morales CE, Roe E, Riera A, Mora JM, Iriarte A, Puig L, Baselga E. Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet. Dermatologic Therapy. 2021; 34(6):e15124. DOI:10.1111/dth.15124. PMID:34486206. IF:3,858.
de Bruin M, Merola JF, Hong CH, Baldrich ES, Ettler K, Sierka D, Delevry D, Chen Z, Rossi AB. Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective. Dermatology and Therapy. 2021; 11(6). DOI:10.1007/s13555-021-00621-w. PMID:34767181. IF:3,661.
Galvan C, Mitja O, Esteban S, Kafulafula J, Phiri T, Navarro I, Roman C, Mtenje H, Thauzeni G, Harawa E, Kaluzi S, Diere M, Mkandawire M, Malizani S, Chifundo A, Utrera M, Roncero M, Martin SL, Vilanova I, Petiti GH, Aranda MVD, Perez NN, Gomez MR, Iranzo P, Garcia PE, De Troya M, Gomez JR, Cardenoso E, Truyols SL, Unanue LA, et al. [Cubiro X, Lopez C]. A facility and community-based assessment of scabies in rural Malawi. PLoS Neglected Tropical Diseases. 2021; 15(6):e0009386. DOI:10.1371/journal.pntd.0009386. PMID:34061851. IF:4,781.
Garcia C, Roe E, Rodriguez B, Amat V, Cubiro X, Puig L, Boronat S. A case report of PHF6 mosaicism: Beyond the classic Borjeson-Forssman-Lehmann syndrome. PEDIATRIC DERMATOLOGY. 2021; 38(4). DOI:10.1111/pde.14636. PMID:34041787. IF:1,997.
Garcia J, Delgadillo J, Vilarrodona A, Querol S, Ovejo J, Coll R, Millan A, Madrigal A, Soria G, Vidal F, Vives J, Herrero MJ, Lopez I, Sauleda S, Contreras E, Grifols JR, Guasch R, Tahull E, Puig L, Masip A, Argelagues E, Muniz E. SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfusion. 2021; 19(2). DOI:10.2450/2021.0259-20. PMID:33539280. IF:5,752.
García-Martínez FJ, Vilarrasa E, Salgado-Boquete L, Martorell A, Pascual JC, Hernández-Martín Á, Silvente C, Ciudad-Blanco C, Andrés Esteban E, Alfageme-Roldán F. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021y;32(3):286-290. DOI:10.1080/09546634.2019.1655524. PMID: 31402725. IF:3,230.
Girolomoni G, de Bruin M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB. Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211002979. DOI:10.1177/20406223211002979. PMID:33854747. IF:4,970.
Gomis-Pastor M, Mirabet Perez S, Roig Minguell E, Brossa Loidi V, Lopez Lopez L, Ros Abarca S, Galvez Tugas E, Mas-Malagarriga N, Mangues Bafalluy MA. Mobile Health to Improve Adherence and Patient Experience in Heart Transplantation Recipients: The mHeart Trial. Healthcare (Basel). 2021;9(4):463. DOI:10.3390/healthcare9040463. PMID: 33919899. IF:3,160.
González-Manso A, Agut-Busquet E, Romaní J, Vilarrasa E, Bittencourt F, Mensa A, Cantó E, Aróstegui JI, Vidal S. Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis. Dermatology. 2021;237(3):365-371. DOI:10.1159/000511045. PMID: 33171462. IF:5,197.
Iznardo H, Baselga E, Mozos A, Szafranska J, Orellana R, Roe E. Net-like superficial lymphatic malformation. PEDIATRIC DERMATOLOGY. 2021; 38(2). DOI:10.1111/pde.14526. PMID:33486776. IF:1,997.
Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211037846. DOI:10.1177/20406223211037846. PMID:34408825. IF:4,970.
Iznardo H, Puig L. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(9):4344. DOI:10.3390/ijms22094344. PMID:33919434. IF:6,208.
Iznardo H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Review of Clinical Immunology. 2021; 17(2). DOI:10.1080/1744666X.2021.1886081. PMID:33538202. IF:5,124.
Julia A, Martinez SH, Domenech E, Canete JD, Ferrandiz C, Tornero J, Gisbert JP, Fernandez A, Dauden E, Barreiro M, Perez C, Queiro R, Lopez FJ, Carazo JLS, Mendoza JL, Alperi M, Montilla C, Venegas JJP, Munoz F, Castaneda S, Lasanta ML, Marsal S, Fonseca E, Rodriguez J, Carreira P, Garcia V, Pinto JA, Puig L, Ricart E, Blanco F, Gratacos J, et al. [Garcia E, Diaz C]. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2021; 75(9). DOI:10.1038/s41430-021-00913-6. PMID:33893449. IF:4,884.
Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, Abuzakouk M, Agondi RC, Al-Ahmad M, Altrichter S, Arnaout R, Arruda LK, Asero R, Bauer A, Ben-Shoshan M, Bernstein JA, Bizjak M, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Busse P, Campos RA, Carne E, Conlon N, Criado RF, de Souza Lima EM, Demir S, et al. [Serra-Baldrich E]. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76(3):816-830. DOI:10.1111/all.14687. PMID: 33284457. IF:14,710.
Lambert J, Hansen JB, Sohrt A, Puig L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00545-5. PMID:33988818. IF:3,661.
Llao J, Masnou H, Romero C, Bargallo A, Gely C, Manosa M, Gordillo J, Garcia E, Domenech E. Noninvasive assessment of liver fibrosis in Crohn’s disease patients exposed to methotrexate. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 2021; 33(6). DOI:10.1097/MEG.0000000000001799. PMID:32804842. IF:2,586.
Lopez C, Falla LM, Roe E, Arostegui JI, Mozos A, Bernal S, Iznardo H, Baselga E. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. JOURNAL OF DERMATOLOGY. 2021; 48(6). DOI:10.1111/1346-8138.15673. PMID:33543522. IF:3,468.
Lopez C, Romani J, Garbayo P, Agut E. Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. JOURNAL OF DERMATOLOGY. 2021; 48(4). DOI:10.1111/1346-8138.15728. PMID:33547675. IF:3,468.
Lopez C, Romani J, Roe E, Giavedoni P, Vidal D, Wortsman X. Ultrasonographic patterns of cutaneous sarcoidosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2021; 40(11). DOI:10.1002/jum.15631. PMID:33459396. IF:2,754.
Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di P, Langan SM, Capon F, et al.; PsoProtect GRP. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2021; 147(1). DOI:10.1016/j.jaci.2020.10.007. PMID:33075408. IF:14,290.
Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, de la Cruz C, Di P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, et al.; PsoProtect CORE GRP. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(1). DOI:10.1111/bjd.19755. PMID:33368145. IF:11,113.
Marron SE, Gomez M, Aragones LT, Goni A, Vilarrasa E, Diaz RM, Garcia FJ, Campos R, Fuentelsaz V, Gilaberte Y, Gracia T, Morales AM, Ros S, Madrid MB, Puig L. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv00529. DOI:10.2340/00015555-3905. PMID:34427316. IF:3,875.
Massey PR, Schmults CD, Li SJ, Arron ST, Asgari MM, Bavinck JNB, Billingsley E, Blalock TW, Blasdale K, Carroll BT, Carucci JA, Chong AH, Christensen SR, Chung CL, DeSimone JA, Ducroux E, Escutia B, Ferrandiz C, Fox MC, Genders RE, Geusau A, Gjersvik P, Hanlon AM, Harken E, Hofbauer GFL, Hopkins RS, Leitenberger JJ, Loss MJ, Del Marmol V, et al. [Ruiz V]. Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients A Delphi Consensus Statement. JAMA Dermatology. 2021; 157(10). DOI:10.1001/jamadermatol.2021.3180. PMID:34468690. IF:11,816.
Mogedas A, Agut E, Marsal MY, Aguilar JL, de la Torre OE. Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. 2021; 79(12). DOI:10.1016/j.joms.2021.07.009. PMID:34391723. IF:2,136.
Muniz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, Millan A, Ene G, Ramiro L, Maglio L, Garcia N, Pinacho A, Jaramillo A, Pero A, Artaza G, Valles R, Sauleda S, Puig L, Contreras E. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfusion. 2021; 19(1). DOI:10.2450/2020.0256-20. PMID:33196417. IF:5,752.
Munoz FZ, Rios M, Roe E, Bernabeu J, Montserrat MT, Puig L, Gich I, Baselga E. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage A Randomized Clinical Trial. JAMA Dermatology. 2021; 157(5). DOI:10.1001/jamadermatol.2021.0596. PMID:33825828. IF:11,816.
Nieto LM, Ciudad C, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, de Eusebio E, Minano R, Escutia B, Gonzalez B, Artola JL, Rubio AA, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, Dobao PD, Navarro R, Suarez R, Carnero L, Vazquez H, Barchino L, Ruiz V, Sanchez P, Lopez JL, Botella R, Feal C, Calatayud AM, Gil P, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. EXPERIMENTAL DERMATOLOGY. 2021; 30(5). DOI:10.1111/exd.14291. PMID:33523531. IF:4,511.
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(6). DOI:10.1111/bjd.20595. PMID:34157132. IF:11,113.
Papp KA, Soliman AM, Done N, Carley C, Wirtz EL, Puig L. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00550-8. PMID:34019229. IF:3,661.
Pereira MP, Zeidler C, Wallengren J, Halvorsen JA, Weisshaar E, Garcovich S, Misery L, Brenaut E, Savk E, Potekaev N, Lvov A, Bobko S, Szepietowski JC, Reich A, Bozek A, Legat FJ, Metz M, Streit M, Serra E, Goncalo M, Storck M, Nau T, Hoffmann V, Steinke S, Greiwe I, Dugas M, Augustin M, Stander S, European Prurigo Project Epp C. Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv000403. DOI:10.2340/00015555-3726. PMID:33320272. IF:3,875.
Pereira MP, Ziehfreund S, Rueth M, Ewering T, Legat FJ, Lambert J, Elberling J, Misery L, Brenaut E, Papadavid E, Garcovich S, Evers A, Halvorsen JA, Szepietowski JC, Reich A, Goncalo M, Lvov A, Bobko S, Serra E, Wallengren J, Savk E, Leslie T, Stander S, Zink A, EADV Task Force P. Google search trends for itch in Europe: a retrospective longitudinal study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(6). DOI:10.1111/jdv.17077. PMID:33295009. IF:9,228.
Piquero-Casals J, Martínez-Martínez L, Alomar A, Rozas-Muñoz E, Juarez C, Puig L. LRP1/CD91 is highly expressed in monocytes from patients with vitiligo – even after repigmentation. Experimental Dermatology. 2021;30(3):390-395. DOI:10.1111/exd.14249. PMID: 33249636. IF:4,511.
Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, Zolkin NA, Kuryshev IV, Petrov AN, Artemeva AV, Zinkina AV. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00554-4. PMID:34060012. IF:3,661.
Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021;32(5):484-491. DOI:10.1080/09546634.2019.1679336. PMID: 31613178. IF:3,230.
Reich K, Hansen JB, Puig L, Konstantinou MP, Warren RB. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(10). DOI:10.1111/jdv.17433. PMID:34076919. IF:9,228.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Román E, Parramón M, Flavià M, Gely C, Poca M, Gallego A, Santesmases R, Hernández E, Nieto JC, Urgell E, Alvarado-Tapias E, Vidal S, Ferrero-Gregori A, Vargas V, Guarner C, Soriano G. Frailty in outpatients with cirrhosis: A prospective observational study. Liver International. 2021;41(2):357-368. DOI:10.1111/liv.14694. PMID: 33030788. IF:8,754.
Roman E, Poca M, Amoros G, Rosell J, Gely C, Nieto JC, Vidal S, Urgell E, Ferrero A, Alvarado E, Cuyas B, Hernandez E, Santesmases R, Guarner C, Escorsell A, Soriano G. Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Scientific Reports. 2021; 11(1):20415. DOI:10.1038/s41598-021-99199-8. PMID:34650096. IF:4,996.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:5,197.
Rusinol L, Amat V, Baselga E, Puig L, Roe E. Prepubertal retroareolar cysts. PEDIATRIC DERMATOLOGY. 2021; 38(5). DOI:10.1111/pde.14786. PMID:34514639. IF:1,997.
Salvador JFS, Gimenez AM, de la Fuente EG, del Castillo JG, Virto A, Blanco IM, Serra E, Llorens P. Managing urticaria in the emergency department: recommendations of a multidisciplinary expert panel. Emergencias. 2021; 33(4). PMID:34251143. IF:5,345.
Sanchez MJ, Docampo A, Mercader P, Gonzalez R, Hervella M, Sanz T, Cordoba S, Sanchez J, Heras F, Gimenez AM, Gatica ME, Pastor MA, Zaragoza V, Carrascosa JM, Garcia B, Ruiz I, Borrego L, Sanchez P, Frutos JO, Armario JC, Garcia J, Fernandez V, Serra E, Silvestre JF. Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index. CONTACT DERMATITIS. 2021; 84(6). DOI:10.1111/cod.13801. PMID:33534191. IF:6,419.
Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. DRUGS IN R&D. 2021; 21(3). DOI:10.1007/s40268-021-00349-0. PMID:34106430. IF:3,203.
Storck M, Sandmann S, Bruland P, Pereira MP, Steinke S, Riepe C, Soto I, Garcovich S, Augustin M, Blome C, Bobko S, Legat FJ, Potekaev N, Lvov A, Misery L, Weger W, Reich A, Savk E, Streit M, Serra E, Szepietowski JC, Dugas M, Stander S, Zeidler C. Pruritus Intensity Scales across Europe: a prospective validation study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(5). DOI:10.1111/jdv.17111. PMID:33411947. IF:9,228.
Suppa M, Fontaine M, Dejonckheere G, Cinotti E, Yélamos O, Diet G, Tognetti L, Miyamoto M, Orte Cano C, Perez-Anker J, Panagiotou V, Trepant AL, Monnier J, Berot V, Puig S, Rubegni P, Malvehy J, Perrot JL, Del Marmol V. Line-field confocal optical coherence tomography of basal cell carcinoma: a descriptive study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(5):1099-1110. DOI:10.1111/jdv.17078. PMID: 33398911. IF:9,228.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Dauden E, Conrad C, Mendes P, Ferreira P, Leite L, Lu JSD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas M, del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung JN, Nogueira M, Chiricozzi A. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2021; 22(4). DOI:10.1007/s40257-021-00598-4. PMID:33786754. IF:6,233.
Tubau C, Puig L. IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy. 2021; 13(4). DOI:10.2217/imt-2020-0253. PMID:33430628. IF:4,040.
Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Review of Clinical Immunology. 2021;17(1):15-25. DOI:10.1080/1744666X.2020.1858802. PMID: 33275064. IF:5,124.
Valdivielso-Ramos M, Martin-Santiago A, Azaña JM, Hernández-Nuñez A, Vera A, Perez B, Tercedor J, Feito M, Vicente A, Prat C, Lopez-Gutierrez JC, Garnacho G, Baselga E, Roe E, Palencia S, Cordero P, Moreno R, Agudo A, de la Cueva P, Torrelo A. Capillary malformation-arteriovenous malformation syndrome: a multicentre study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2021;46(2):300-305. DOI:10.1111/ced.14428. PMID: 32840927. IF:4,481.
van KR, Tzellos T, Guillem P, Benhadou F, Cuenca C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos EJ, Jemec G, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak L, Molina A, Moltrasio C, Pinter A, Potenza C, Romani J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2021; 85(2). DOI:10.1016/j.jaad.2020.12.089. PMID:33484766. IF:15,487.
Vidal S, Puig L, Carrascosa JM, Gonzalez A, Ruiz JC, Velasco AM. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(13):6740. DOI:10.3390/ijms22136740. PMID:34201664. IF:6,208.
Yélamos O, Alejo B, Ertekin SS, Villa-Crespo L, Zamora-Barquero S, Martinez N, Domínguez M, Iglesias P, Herrero A, Malvehy J, Puig S. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):143-149. DOI:10.1111/jdv.16559. PMID: 32365242. IF:9,228.

ASSOCIATED GROUPS

Dermatology

Main lines of research

Challenges

Group coordination

Members

Publications 2023

Publications 2022

Publications 2021

Main lines of research

Challenges

Group coordination

Members

Publications 2023

Publications 2022

Publications 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau